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Abstract 
Pancreatic Ductal Adenocarcinoma (PDAC) may soon become the third-leading cause of 
cancer-related death in the United States. Aside from curative resection of tumors, there is 
no highly effective therapy to treat PDAC. Because patients are usually diagnosed in the 
late stage of the disease, more than 80% of them are not eligible to undergo surgery, which 
results in a post-diagnosis survival rate of three to four months, and an extremely low five-
year survival rate of 6%. Despite discouraging current clinical outcomes, clinical trials 
treating PDAC patients with adjuvant therapy combined with IFN-a (IFN), Fluorouracil 
(5-FU), Cisplatin (CDDP), and radiation have shown to improve patients’ two-year 
survival rates by 20-41%, and improve their five-year survival rates by 35%. These clinical 
trials show that IFN-therapy is now one of the few therapeutic regimens that can 
significantly improve the short- and long-term survival of PDAC patients. 
Despite its high efficacy, the drawbacks of IFN therapy included high IFN systemic 
toxicity, which resulted in increased patient drop-out rates in clinical trials, and low levels 
of the cytokine in tumors, which hampered the chemo-radio-sensitization capability of IFN 
during therapy. To attempt to improve the efficacy and overcome the drawbacks of IFN 
therapy, we studied the use of IFN-expressing replication competent oncolytic adenovirus 
(OAd) vectors in combination with chemoradiation mimicking the aforementioned 
chemoradiation and IFN-based clinical trials. Because IFN therapy can stimulate a tumor-
specific immune response, we first evaluated the anti-tumor effect of oncolytic adenovirus 
vector expressing hamster IFN (OAd-hamIFN) in a syngeneic immunocompetent PDAC 
hamster model. To further understand the interaction between IFN-expressing OAd and 
chemotherapy, radiation, and chemoradiation, and to evaluate the therapeutic effect of the 
virus used in treatments mimicking the IFN therapy, we also tested the effect of a human 
IFN-expressing oncolytic adenovirus (OAd-IFN) in immunodeficient mice bearing human 
PDAC xenografts. To increase infectivity of OAd-hamIFN in hamster pancreatic cancer 
cell lines, we included the RGD-4C (Arginive-Glycine-Aspartic) motif in the HI loop of 
OAd-hamIFN fiber. This modification is known to shift viral tropism from the Coxsackie 
and Adenovirus Receptor (CAR) to integrins αvβ3 and αvβ5, which are widely expressed 
in hamster pancreatic cancer cell lines. To increase infectivity of OAd-IFN in human 
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pancreatic cancer cells lines, we replaced the adenovirus type 5 fiber with the chimeric 
adenovirus 5/3 fiber, which consisted of the fiber of adenovirus type 5 with the knob of 
adenovirus type 3. This modification has been proven to shift viral tropism from CAR 
receptor, which shows low expression in human pancreatic cancer cells, to Desmoglein 
type-2 and CD46 proteins, which are widely expressed in human pancreatic cancer cell 
lines. To improve spreading in tumors and oncolytic effect of both OAd-hamIFN and OAd-
IFN in PDAC cells, and to achieve replication-dependent expression of IFN, we included 
the Adenovirus Death Protein (ADP) and respective IFN genes in the adenovirus (Ad) E3 
region. To restrict the replication of human IFN expressing OAd vector (OAd-IFN) in 
human PDAC cells, we added the cyclooxygenase-2 (Cox-2) promoter upstream of the Ad 
E1 region, which is the region responsible for initiating viral replication. 
Combinations of 5-FU, radiation, and 5-FU + Radiation with OAd-hamIFN in hamster 
PDAC cells, or with OAd-IFN in human PDAC cells, resulted in highly synergistic and 
cytotoxic combinations in vitro. Studies in the syngeneic hamster PDAC model showed 
that including OAd-hamIFN in combination with therapeutics used in IFN therapy 
improved treatment efficacy, and that using the virus in treatment mimicking the IFN 
therapy (OAd-hamIFN + 5-FU + Radiation) was the most effective treatment strategy in 
the study. When we analyzed the effect of OAd-IFN in combination with 5-FU + CDDP in 
human PDAC cells, the combinations were antagonistic and weakly cytotoxic. But adding 
radiation to the treatment (OAd-IFN + (5-FU + CDDP) + Radiation) overcame the 
chemotherapy antagonism, which resulted in highly synergistic and extremely potent 
treatments in vitro and in mice bearing PDAC xenografts.  
Because radiation eliminated the antagonism of chemotherapy to the virus in vivo, we 
tested different radiation protocols in combination with OAd-IFN in mice bearing PDAC 
tumors. We concluded that administering radiation before infecting tumors with OAd-IFN 
improved treatment efficacy and that using radiation before OAd-IFN infection should 
potentiate the effect of Cox-2 controlled IFN-expressing OAds in combination with 
chemoradiation. 
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In summary, our data strongly support including an IFN expressing OAd in treatments 
mimicking IFN therapy. As this therapy is one of the few therapeutic regimens shown to 
improve patients’ short- and long-term survival rates, developing a virus-based IFN 
treatment protocol may result in a highly effective means to treat PDAC.  
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1. Background 
1.1.  History of virotherapy 
The years leading up to the twentieth century marked the beginning of modern medicine. 
Charles Darwin introduced the theory of evolution and Gregor Mendel began the field of 
genetics by describing basic concepts of genetic inheritance. Louis Pasteur and Robert 
Koch founded modern microbiology, and Claude Bernard enunciated principles about the 
internal environment of the body that contributed to the development of the fields of 
physiology, biochemistry, and pathology. These advances in biological sciences were 
accompanied by innovations in the field of human medicine with the invention of the 
stethoscope, use of x-rays, development of anesthesia, and the treatment of infections. 
Despite considerable scientific, technological, and biological progress, there were no 
reports of appreciable improvements in the treatment of human malignances such as cancer. 
Cancer treatment was restricted to primitive surgical procedures, and the use of non-
effective therapeutic approaches like the use of castor oil and arsenic (1, 2). Despite further 
advances in the treatment of malignances with emerging chemotherapies and the use of 
radiotherapy in the 1940s, these methods still were not effective in improving the long-
term survival rates of patients affected by many types of cancers, including pancreatic 
cancer. There still is a pressing need to find alternative and efficacious methods to treat 
cancer. 
The relationship between viruses and human diseases has two contrasting aspects: 1) 
oncogenic viruses can induce carcinogenesis (3, 4); and 2) other viruses can be effective in 
treating cancer. Using viruses to treat cancer was not premeditated, but coincidental. The 
development of the field of virotherapy began at the end of the nineteenth century with the 
observation that leukemia patients who became naturally infected with influenza had a 
brief remission in the course of their disease. Although complete leukemia remission was 
never reported, viruses started to be considered as a promising therapeutic modality to treat 
malignancies (1, 5). Incidences occurred where patients with leukemia (5, 6), Hodgkin’s 
disease (7, 8) , and Burkitt’s lymphoma (9) would also show disease regression when 
concomitantly and naturally infected with the measles virus. Similar case reports were also 
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described in cancer patients who were naturally infected with the hepatitis virus. In fact, 
infection of Hodgkin’s disease patients with the hepatitis virus is historically cited as one 
of the first attempts to use a virus as a therapy to treat cancer (1). With the evolution and 
experimentation in the virotherapy field, viruses causing serious disease such as West Nile, 
Uganda, dengue, and yellow fever viruses were casually tested in cancer patients. Because 
of the lack of efficacy and safety when using these viruses, there was a gradual shift in the 
virotherapy field to study the efficacy of adenoviruses, poxviruses, picornaviruses, 
paramyxoviruses, and herpes viruses in treating malignancies. Talimogene laherparepvec 
(Imlygic or T-VEC), is a herpes simplex virus that was modified and tested in the treatment 
of melanoma (10-12). In 2015, Imlygic was the first vector approved by the Food and Drug 
Administration for use in treating melanoma patients in the United States, and it is also 
being used in Europe (13).  
In summary, the widespread testing and use of viruses in treating malignancies greatly 
advanced and built the foundation of virotherapy as a modality to treat cancer. Through 
extensive experimentation and observation in the field, there are several important key 
points about using viruses to treat cancer: a) viruses can be used to eliminate tumors and 
can be well tolerated by the patients; b) successful tumor regression is usually seen in 
younger patients with compromised immune systems (e.g., leukemia or lymphoma 
patients). 
1.2. History of adenovirus use in virotherapy 
Using adenoviruses to treat cancer began in the early 1950s when the adenovirus—A.K.A. 
adenoidal-pharyngeal-conjunctival virus—was identified as an oncolytic agent in pre-
clinical models (1). Contrary to previously used viruses such as the hepatitis and West Nile 
viruses, which provoked life-threatening side effects in patients, oncolytic adenoviruses 
(OAd) only induced mild common cold-like symptoms (14). The safety of the adenovirus 
in patients rapidly promoted this viral agent for use in clinical trials to treat cervical cancer 
(15). Viral administration was safe when given intravenously, intravascularly, and intra-
arterially to women presenting with epidermoid carcinoma of the cervix. But although the 
use of OAd resulted in remarkable localized tumor necrosis, the immune system quickly 
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eradicated the virus, and none of the trials showed a significant increase in the rate of 
patient survival (16, 17). This was the first indication of the impact of pre-existing 
immunity against adenovirus in the treatment efficacy.  
To date, there are 67 identified serotypes of adenovirus, and they are subdivided into groups 
A through G. Groups A, F, and G have been associated with gastrointestinal tract diseases; 
groups B, D, and E with conjunctivitis outbreaks; and groups B, C, and E with upper 
respiratory tract infections (18-20). Human adenoviruses have been studied extensively 
over the years, and there is extensive knowledge about their replication cycle, genome, 
structure, cells, and pre-clinical models susceptible to viral replication. Human Adenovirus 
type 5 (Ad5), which belongs to group C, is the most genetically modified and classically 
used serotype in cancer virotherapy (21).  
A review of the literature in this area thoroughly describes the use of tissue-specific 
promoters to restrict viral replication to specific cancer types; retargeting of viral infection 
by fiber modification; elimination of antibody neutralization by modifying highly antigenic 
regions of the virus; and modifying the viral genome to eliminate regions responsible for 
initiating viral replication in healthy tissues (21-28). After the aforementioned clinical trials 
where wild type Ad5 was used to treat cervical cancer, a variety of genetically modified 
adenovirus vectors were tested in multiple clinical trials targeting pancreatic cancer, 
ovarian cancer, head and neck cancer, and other cancer types (21, 29-32). Although many 
of these trials did not provide enough evidence for the United States Food and Drug 
Administration to approve OAd for treating the targeted cancers, in 2005 the State Food 
and Drug Administration in China approved a genetically modified Ad5 based vector 
(H101) as a drug to treat head and neck cancer (33). This was the first time in the history 
of OAd use that a replication-controlled OAd vector was proven to be efficacious in 
treating a solid tumor. Despite steady and exponential progress in the virotherapy field, the 
fatal death and negligent administration of a genetically modified adenovirus to correct a 
metabolic syndrome in a teenager caused the quick cessation of OAd use and skepticism 
in the field (34-36). 
 
 4 
2. Adenovirus 
2.1. Structure and replication cycle 
Human adenoviruses are non-enveloped, double-stranded DNA viruses belonging to the 
Adenoviridae family (Figure 1). The viruses measure 70-90 nm and possess an icosahedral 
capsid encasing a tightly packed 36kB viral genome (37). As mentioned above, there are 
67 identified adenovirus serotypes, which are subdivided into groups A–G. Human 
Adenovirus type 5 (Ad5), which belongs to group C, is the most genetically modified and 
classically used serotype in cancer virotherapy (21). Hexon is the most abundant protein in 
the viral capsid (approximately 240 units total), and its expression in the late phase of the 
virus-replication cycle is commonly used to track viral replication in vitro and in vivo (24, 
38). Viral fibers are individually connected to each of the 16 penton bases present in the 
capsid. The adenovirus fiber is a homotrimer with each subunit consisting of three domains: 
the amino-terminal tail, which is connected to the penton base protein; the shaft, which is 
comprised of a 15 residues motif repeated 22 times; and the knob, which established the 
primary contact between the virus and the cellular receptor (39-41). 
 
 
Figure 1: Human adenovirus structure. Figure reproduced from reference (37) 
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Except for adenoviruses belonging to group B, which bind to CD46 surface proteins (42), 
all other adenovirus groups bind to the coxsackievirus and adenovirus receptor (CAR)(43). 
After high affinity binding between the fiber knob and adenovirus receptor (CAR or 
CD46), there is a secondary binding interaction between the RGD (Arg-Gly-Asp) motif 
located on the penton base of the adenovirus capsid and cellular integrins, fibronectins, or 
vitronectins receptors. There are over 20 known integrins that can be recognized by the 
RGD motif. Among these, the most common ones are avb3, avb5, avb6, and avb8. Of 
the fibronectin and vitronectin receptors, the most common ones recognized by the RGD 
motif are: a5b1, ,a8b1, and avb1-8 (44). Complete binding of virus to the receptor induces 
viral-clathrin mediated endocytosis followed by fusion of clathrin coated pit and cellular 
lysosomes (late endosome formation). Acidification of late endosome induces capsid 
uncoating by conformational changes in the viral capsid proteins leading to shedding of 
the penton base, pIIIa protein, fiber, and peripentonal hexons. Protein pVI, which contains 
an amphipathic domain in its N-terminal tail, interacts with the endosomal membrane and 
releases uncoated capsid into the cellular cytoplasm. The uncoated capsid interacts with 
cellular microtubules and it is presumed that the motor proteins (e.g., dynein and kinesin) 
direct viral capsid to the nuclear pore (37). Filament protein CAN/Nup214 and nuclear 
histone H1 bind to the capsid hexon protein and stably dock the capsid in the nuclear pore 
complex (NPC). Retrograde movement of capsid driven by microtubular motor proteins 
pull the capsid in the opposite direction of the NPC, which results in capsid disruption and 
viral DNA release. The exact method of transport of viral DNA through the NPC is 
controversial, but there is evidence that the histone H1 and hsc70 mediate the process (45, 
46). Once inside the nucleus, the transcription process starts. The adenovirus genome is 
divided into early genes (E1, E2, E3, and E4), late genes (L1, L2, L3, and L5), the VA-
RNA region. The L5 region is also classified as the fiber region in the adenovirus genome 
(47). Both extremities of the adenoviral genome (or the Inverted Terminal Repeats (ITRs)), 
are covalently bound to the Terminal Protein (TP) and possess an origin of replication. The 
NF-1 and Oct-1 cellular transcription factors bind to the 5’ origin of replication and 
contribute to the formation of a transcription pre-initiation complex that enhances the start 
of viral DNA replication.  
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The replication process starts by the expression of genes from the adenoviral E2 region 
encoding for TP precursor (pTP), adenovirus DNA polymerase (Ad-pol), and DNA-
binding protein (DBP). In conjunction with the NF-1 and Oct-1 factors, the DBP binds and 
helps in the remodeling of the pre-initiation complex. Protein-primed DNA synthesis starts 
by the covalent addition of a dCMP residue to the pTP. After some intermediary processes 
and covalent modifications of the TP by the Ad-pol, the polymerase detaches from the pTP 
region. After it detaches, there is an increased rate of polymerization and proofreading by 
the Ad-pol enzyme that continues the process of viral DNA extension and replication. In 
the final stages of replication, the pTP is cleaved by a viral protease resulting in TP, which 
follows attached to recently formed viral DNA. This step completes the replication process, 
and the newly formed viral DNA is ready to be encapsidated (48). The encapsidation 
process occurs when freshly formed capsids are transported through the nuclear pore by 
the protein VI, which is a structural protein located below the 12 vertices of the adenoviral 
capsid. The protein VI possesses nuclear localization signals in its C-terminus region, and 
works as an adaptor that facilitates hexon import through the nucleus (49). 
2.2. Adenovirus early gene expression 
Expression of adenovirus early genes (E1-E4) is essential to initiate and complete 
successful viral replication in host cells. Each of the adenovirus’s early regions is controlled 
by an individual promoter. Expression of the adenovirus’s E1 region results in the 
transactivation of the subsequence promoter regions (E2, E3, and E4) and tightly 
orchestrates the progression of the viral cell cycle. Proteins E1A, E1B 19K, and E1B 55K 
are some main products of adenoviral E1 region. E1A binds to the cellular Rb and releases 
the E2F transcription factor. Free E2F drives the cell cycle to the S-phase and boosts the 
cell’s capacity for DNA replication and, consequently, protein production (50). Proteins 
E1B 19K and E1B 55K, respectively, inhibit and target for degradation cellular Bcl-2 and 
p53 proteins (51, 52). Because Bcl-2 is a pro-apoptotic protein, and p53 is a tumor 
suppressor that also induces apoptosis, the degradation of both proteins will ensure that the 
infected host cell progresses to the S-phase without undergoing apoptosis. As discussed 
above, the E2 region of the adenovirus genome is responsible for expressing the viral DNA 
polymerase. The E3 region encodes for many different gene products, most of which are 
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related to inhibiting the host immune system’s identification of virus infected cells. The 
E3-gp19K protein, for example, prevents the loading of intrinsic cellular peptides 
(including viral peptides) into the class I major histocompatibility-mediated antigen 
presentation complex (MHC-I). As a result, the identification and elimination of infected 
cells by the cytotoxic T lymphocytes (CTLs) is blunted (53, 54). Another important 
function of the adenoviral E3 region is the expression of the Adenoviral Death Protein 
(ADP). ADP is a palmitoylated integral membrane glycoprotein that is expressed early on 
in the viral cell cycle, but is greatly amplified during later stages of infection. ADP 
expression is correlated with increased cell lysis and viral spreading (54). Although it is 
not clear how ADP causes cell lysis, the protein is found in the nuclear membrane and 
Golgi complex. Because the final viral assembly and DNA encapsidation occurs in the 
nucleus (49), it is possible that ADP lysis of the nuclear membrane makes the process of 
viral release more efficient. High ADP expression becomes particularly important in 
designing oncolytic vectors to kill cancer cells. Since most of the E3 region’s genes are not 
essential, it is possible to induce massive ADP expression by deleting most genes from this 
region and reintroducing ADP to the same location (54). 
The E4 region contains a variety of genes that modulate transcription, cell cycle, cell 
signaling, and interfere with cellular DNA repair (55). The E4 region also contains genes 
that are not essential to viral replication and that can be replaced by other transgenes (e.g., 
enzymes, cytokines, prodrugs, and others). Although both the E3 and E4 regions can lead 
to high expression of transgenes, the E4 region has been found to produce comparatively 
higher yields of expression (55, 56). 
2.3. Adenovirus late gene expression 
The adenovirus’s late-phase genes—L1, L2, L3, L4, and L5— encode capsid proteins or 
proteins that are responsible for capsid assembly. The Major Late Promoter (MLP), which 
is minimally active during the first phase of adenovirus replication, controls the expression 
of these genes. With the expression of the Iva2 and pIX (minor capsid proteins), 
transcription through the MLP becomes fully activated, and the MLP strongly expresses 
the remaining major and minor capsid proteins and adenovirus fiber (57). During late gene 
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expression, protein synthesis in the host cells is heavily suppressed because the adenovirus 
tripartite leader (TPL) shuts down the host’s cellular cap-dependent mRNA translation. 
At this stage, the cell’s protein translation machinery becomes exclusively dedicated to 
producing adenovirus proteins. Adenovirus TPL is composed of three introns (TPL 1–
3), and mediates the nuclear export, translation, and stability of late viral mRNAs that will 
in turn be translated into adenoviral-structural proteins in a cap-independent manner (58). 
Viral structural proteins are comprised of hexon, fiber, penton, polypeptides core proteins 
V and VII, as well as minor polypeptide proteins: IIIa, VI, VIII, IX, and X-XII. Besides 
playing a role in the agglutination of cells and the induction of the host’s antibody response, 
these proteins are essential to maintaining viral structure and infectivity (59). 
2.4. Adenovirus VA-RNA 
The adenovirus-associated RNA (VA-RNA) are non-coding RNA transcripts that are 
abundantly expressed during adenovirus replication. RNA concentrations can reach up to 
108 DNA copies per cell and measure 150–200 nucleotides long. Approximately 80% of 
all adenoviruses, including Ad5, encode two distinct VA-RNA transcripts (VA-RNAI and 
VA-RNAII) and both VA RNAs are transcribed by the cellular RNA Polymerase III. The 
expression of VA-RNA is essential during viral replication because its absence during 
replication can result in about a about 60-fold decrease in viral yield in infected cells. 
Beginning at 18hrs post-infection, the VA-RNAI and VA-RNAII accumulate in the 
cytoplasm, and their peak expression happens by the end of the lytic cycle (24hrs post-
infection) (60). 
Although the VA-RNAs have several proposed functions, their main function is to inhibit 
the shutdown of protein translation in the host cell through RNA-activated protein kinase 
(PKR)(60). Expression of PKR is induced by type I Interferons (IFN-a and IFN-b), which 
orchestrate an anti-viral cellular response against DNA and RNA viruses. The IFNs act in 
a species-specific manner and exert their actions through cell-surface receptors (IFNAR-1 
and IFNAR-2) (61, 62). The presence of double-stranded RNA in the cellular cytosol 
results in the transcriptional activation of the type I IFN promoters and the expression of 
IFN response genes. As the result, production of type I IFN by the infected cells is 
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stimulated, and newly expressed IFN acts in a paracrine and autocrine manner to stop the 
viral infection from progressing to neighboring cells.  
Although IFN-stimulated expression of MHC-I, PKR, Mx GTPase protein, and inducible 
nitric oxide synthase all contribute to protecting the cell against viral infection, the 
stimulation of PKR is markedly important in this process (61). PKR can inhibit protein 
translation in the host cells by performing serine phosphorylation in the cytosolic eIF-2 
(63). Phosphorylation of eIF-2 affects the formation of the translation initiation complex 
in cells, which, in turn, shuts down protein translation. The VA-RNA produced by the 
adenovirus can co-localize with the translation-initiation complex in infected cells and 
inhibit the phosphorylation of eIF-2. It also helps in preferential protein translation from 
viral RNA, which then forces the cell to progress with a massive production of viral 
proteins and newly formed virions regardless of IFN anti-viral effects (60, 61). 
2.5. Oncolytic Adenoviruses (OAds) 
Because OAds display a lytic-replication cycle—meaning that they disrupt the host’s cells 
by the end of replication—they are an attractive tool for cancer therapies since they can 
cause debulking and elimination of solid tumors (21, 24, 38). During oncolysis, OAds 
release tumor-specific peptides into the host’s immune system, which stimulates formation 
of an anti-tumor immune response (21, 64). Conditionally Replicating Adenoviruses 
(CRADs) are replication-competent OAds that are designed to replicate and kill a specific 
type of target cell (eg. cancer cells) (21, 65). Targeted replication of CRADs in cancer cells 
can be achieved by introducing a cancer-specific promoter upstream of the E1 region of 
the viral genome. Because there is differential expression of this promoter in cancer tissue 
as compared to normal tissue, CRADs restrict their replication to cancer cells avoiding 
normal cells (21). Another way to target the replication of CRAds in cancer cells is to delete 
the adenovirus’s E1A and E1B region. Because protein coded by these two regions induce 
E2F release from Rb, and target p53 for degradation, modified vectors will restrict their 
replication to cells that are deficient in Rb and p53. Since most cancer cells lack Rb and 
p53, but normal cells do not, CRADs target their replication in cancer cells (21, 65-67). It 
also is possible to modify the fiber in OAds to target receptors that are differentially 
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expressed in cancer cells, or to gain infectivity to a cell type that lacks its natural receptor 
(CAR). For example, pancreatic cancer cells show a very low expression of CAR, but show 
a higher expression of mesothelin or desmoglein type-2 receptors. Substituting the knob of 
the Ad 5 fiber for the knob of Ad type 3 can shift the tropism of Ad5 from CAR to the 
mesothelin or desmoglein type-2 receptors, which can increase the infectivity of modified 
Ad5 to pancreatic cancer cells (21, 38, 56). 
3. Immune response vs adenovirus-based therapy 
3.1. Effect of preexisting immune response in adenovirus-based therapy 
Evoking an immune response against adenovirus may or may not be beneficial during 
cancer treatment. One potential obstacle when using the virus to treat cancer is that many 
patients have pre-existing anti-adenovirus neutralizing antibodies. The presence of these 
antibodies can reduce treatment efficacy because they neutralize and eliminate a 
considerable number of viral particles during therapy (68). Despite this limitation, there 
are reports showing that the presence of anti-adenovirus antibodies in patients before or 
during treatment using the virus does not affect therapy efficacy. For example, in the 
Cellgenesis prostate cancer clinical trial based on the use of a Prostate Specific Antigen 
(PSA) replication controlled OAd, levels of adenovirus-specific antibody titers in patients 
did not correlate with decreased therapeutic efficacy or increased patient PSA levels (69). 
These data showed that although anti-adenovirus antibodies were present, the viral therapy 
was effective and the PSA levels were diminished after therapy. Another example is a 
recent clinical trial and subsequent report describing the intravenous administration of a 
chimeric adenovirus vector (Psioxus) for the treatment of colon cancer (70). In this trial, 
although treatment with the Psioxus vector elicited an antibody response, the patients still 
experienced a reduction in tumor size. 
3.2. Effect of innate immune response during Adenovirus-based therapy 
The earliest sensors that trigger an innate immune response against the adenovirus are the 
a) binding of the adenovirus fiber to the CAR receptors; and b) binding of the RGD motif 
in the adenovirus penton base to the cellular integrins or fibronectin receptors. When the 
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virus fiber binds to CAR receptors, there is clustering of junctional adhesion molecule-like 
protein (JAML) and the activation of phosphoinositide 3-kinase (PI3K), which eventually 
leads to the activation of the NF-kB pathway and the production of pro-inflammatory 
chemokines and leukocyte recruitment (71). When the RGD motif binds to cellular 
integrins, especially the avb3, it leads to the production of IL-1 beta, which can also be 
stimulated when viral DNA binds to the Toll-Like Receptor 9 (TLR9) in the late 
endosomes. The downstream pathway of TLR9 activation stimulates the NF-kB pathway, 
which, in turn, produces chemokines and cytokines, including IL-1.  
Of the many ways that the innate immune response can fight a pathogen, the stimulation 
of IFN-type I (IFN) and the Interleukin-1 (IL-1) pathways are the main innate immune 
responses to eliminate virus infection. The chemokines and cytokines that are induced by 
the IFN and IL-1 pathways induce the expression of P-selectin, E-selectin, and a-integrins 
in blood vessels (72). These cytokines also induce the opening of blood-vessel 
fenestration, which leads to the extravasation of cellular pro-inflammatory infiltrate to 
the infected areas. The pro-inflammatory infiltrate is usually comprised of leukocytes, 
CD11b+ neutrophils, NK cells, and macrophages. This cellular infiltrate eliminates 
infection and infected cells.  
In most cases, treatment with adenovirus vectors also can lead to high levels of infectious 
particles trapped in the liver. As a result, liver-resident macrophages (Küpffer cells) 
phagocyte the virus and release pro-inflammatory cytokines and chemokines such as tumor 
necrosis factor-alpha (TNF-α), IP-10, and RANTES. Depending on the dose of adenovirus 
used to treat the patient, and the level of viral particles that the patient retains in his or her 
liver, the induction of cytokines can be extremely elevated and lead to acute liver failure 
(35, 73). 
Although the activation of an innate immune response can be extremely beneficial in the 
treatment of cancer patients (74), it also can lead to fast viral clearance (80%) in the host 
or cancer patient within the first 24 hours after infection. On the other hand, the stimulation 
of an innate immune response against the virus can boost treatment efficacy when CTLs 
and Natural Killer (NK) cells are recruited to the infection site by chemokines, and these 
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cells eliminate virally infected cells, which in the case of OAd therapy, are cancer cells 
(21). Also, when using an oncolytic adenovirus during treatment, virus-induced oncolysis 
can broaden the repertoire of cancer-specific peptides presented to the immune system, 
stimulate CD8 tumor-specific T-cells, and cause immunological awakening at the cancer 
site (75). Although tumors are immunosuppressed environments, OAd oncolysis results in 
the expression of chemokines and cytokines, which, in turn, coordinate the activation of 
NK cells and the formation of cellular immunity at the cancer site (75, 76). Oncolysis also 
can make tumors resistant to PD-1/PD-L1 immunotherapy, susceptible to this therapeutic 
approach (75). Patients who develop an anti-tumor immune response, especially with 
tumor CTLs and NK cells, are reported to have delayed disease recurrence and a better 
ability to fight metastases and micrometastases (74). 
3.3. Effect of acquired immune response in adenovirus-based therapy 
During infection, professional antigen-presenting cells (APC), such as dendritic cells and 
macrophages, phagocytize viral particles and present their viral specific peptides on their 
class II major histocompatibility-mediated antigen presentation complex (MHC-II). APCs 
then migrate to the draining lymph nodes and prime and activate native T cells against the 
viral peptides. Activated T-cells (CD4+ and CD8+) leave the lymph nodes and scan the 
body to identify viral antigenic epitopes presented in the MHC-I of infected tissues. When 
activated T-cells recognize an antigen, they produce IFN-γ and express pro-inflammatory 
cytokines such as IL-1, IL-6, and TNFα which aids in the recruitment and activation of 
leucocytes.  The activation of B cells through phagocytosis or by contact with activated T-
cells results in the production of high titers of adenovirus-specific antibodies and the 
formation of adenovirus specific memory B cells (77, 78). Because as much as 80% of the 
human population has been exposed to at least one of the 67 adenoviruses serotypes during 
their lifetime (77), most of the population has adenovirus-specific memory B cells against 
at least one serotype of the virus. Therefore, the treatment of cancer patients using 
adenovirus vectors results in the rapid production of high titers of anti-adenovirus 
antibodies that might or may not interfere with therapeutic efficacy.  
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There are several ways to avoid the deleterious effects of a patient’s pre-existing immunity 
to the adenovirus and improve treatment efficacy. Because most of the anti-adenovirus 
antibodies recognize viral capsid proteins, covalent modifications of capsid 
immunodominant peptides with FDA-approved Polyethylene-Glycol (PEG) can inhibit the 
immediate production of antibodies (79). Encapsulation of the virus vector with inert 
polymers can also achieve the same goal (80, 81). Immunosuppression with 
dexamethasone (82), cyclosporine (83), cyclophosphamide (84), deoxyspergualin (85), and 
Tacrolimus (86) are also pharmacological alternatives that can be administered to patients 
before they are treated with an adenovirus vector.  
As previously mentioned, although there are many ways to decrease the effect of a 
preexisting immune response against the adenovirus during therapy, there is no clear 
clinical indication that the presence of anti-adenovirus neutralizing antibodies can 
eliminate the efficacy of adenovirus-based cancer therapies (69, 70). Despite the lack of 
persuasive clinical evidence, however, it is true that the presence of anti-adenovirus 
neutralizing antibodies have the potential to eliminate a great number of the viral particles 
when a virus vector is administered intravenously. The role of neutralizing antibodies 
during adenovirus therapy is controversial. Some reports, for example, indicate that the 
presence of antibodies can increase liver toxicity by stimulating elevated antibody 
mediated virus phagocytoses by Küpffer cells in the liver, which can result in high 
expression of pro-inflammatory cytokines leading to liver failure.  Contrary to that, other 
reports show that the presence of antibodies actually mitigates virus-induced liver toxicity 
(77). 
4. In vivo models to study human oncolytic adenovirus therapy 
4.1. Mouse models 
While mice models are widely used to test the efficacy of the adenovirus in cancer 
treatment, mice are not permissive to human adenovirus replication (87-89). Infection of 
murine cancer cells with human adenovirus type 5 (Ad5) is reported to result in 1000-fold 
lower viral yields compared to infection of human cancer cells with Ad5 (88, 89). There 
also is evidence that viral DNA and RNA are greatly reduced in mice cells, as is the 
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expression of viral early and late genes (88). Published studies showed that intravenous 
administration of Ad5 in mice resulted in detectable lysis of liver cells, but replication of 
the virus was incomplete and there was no increase in adenovirus titers in the blood over 
time. Although the adenovirus’s natural site of replication in humans is considered to be 
the lungs, studies trying to assess Ad5 replication in mice showed that the virus displayed 
transient or very low levels of replication in murine lung cells (89). The main disadvantage 
of using mice to study adenovirus-based therapies is the inability to clearly analyze the 
toxicity of an adenovirus vector in normal tissue. This limitation, however, does not 
invalidate using mice in adenovirus cancer research. Immunodeficient mice can be 
engrafted with human cancer cell lines or patient-derived tumors, which allows an isolated 
assessment of adenovirus-therapy efficacy in these tissues without the interference of the 
immune response. In this scenario, mice can provide an in vivo assessment of the inhibition 
or potentiation of drugs in viral replication, the spreading of the virus in human tumors, 
and the susceptibility of human tumors to adenovirus therapy. On the other hand, in case 
studies involving the tumor microenvironment are conducted, it is necessary to be aware 
that although human cancer cells are injected in the animals, mice fibroblasts and other 
mice derived cells will be composing most of the tumor microenvironment.  
4.2. Hamster models 
Golden Syrian hamsters (Mesocricetus auratus) are one of the few animals considered to 
be permissive for human adenovirus replication (87, 90). Intranasal infection of hamsters 
with Ad5 showed that there is a sustained viral replication in the lungs followed by a 
gradual increase in viral titers in the blood over time (91). Previous studies that assessed 
replication of the virus in vitro also confirmed productive adenovirus replication and 
expression of late gene products in a variety of hamster cells (89). Unlike mice, hamsters 
can be used to assess virus toxicity in normal tissues during adenovirus-based treatments. 
Hamsters can also be extremely useful when analyzing the effectiveness of adenovirus 
therapy in cancer treatment, especially pancreatic cancer. Since hamsters have a very low 
variability in their major histocompatibility complex genes (Hm-1)(92) (especially if they 
are inbred for research), use of hamster pancreatic cancer cells lines such as HP1, HAPT-
1, H2T, PC1, and WD to grow tumors in these animals results in a syngeneic 
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immunocompetent model of pancreatic cancer (93, 94). This model allows the assessment 
of adenovirus replication in noncancerous tissues; safety of adenovirus replication 
controlled by specific promoters; the effect of anti-adenovirus immune response during 
treatment; and the effect of anti-tumor immune response during therapy. It is also possible 
to generate more clinically translatable data and have a clearer understanding of how to 
manipulate OAd-based therapies to achieve maximum effect in cancer patients. While a 
syngeneic immunocompetent cancer model is extremely resourceful, the availability of 
reagents to assess the immunological response in hamsters still is very limited. Although 
this is not an insurmountable obstacle, it still poses limitations on the thoroughness of 
immunological analyses that can be done using these animals.  
5. Pancreatic cancer 
Pancreatic cancer may soon be the third leading cause of cancer-related death in the United 
States (95). In 2017, about 53,670 people will be diagnosed with pancreatic cancer, and 
43,090 will die from the disease. Pancreatic cancer accounts for 3% of all cancers in the 
U.S. and about 7% of all cancer deaths. The risk factors associated with the disease are 
both changeable and non-changeable. The changeable risk factors include smoking, excess 
weight and obesity, and exposure to heavy metals,  and carcinogenic substances. The non-
changeable risk factors are age (the average age of detection is 71), race (African–
Americans are at greater risk than Caucasians), family history, genetic inherited syndromes 
(possessing KRAS, P53, P16, and other shared pancreatic-cancer mutations), diabetes, 
pancreatitis, liver cirrhosis, and stomach problems (e.g., infection with Helicobacter 
pylori) (96).  
The early stages of pancreatic cancer are usually asymptomatic. The majority of patients 
are diagnosed when the disease spreads and starts to compromise the functions of other 
organs. Although levels of cancer markers CA 19-9 and carcinoembryonic antigen (CEA) 
are closely correlated with pancreatic cancer, detectable levels are mostly found in 
advanced cases of the disease. And even though a tumor may have spread beyond the 
pancreas, not all patients show elevated levels of these markers (96-98).  
Pancreatic cancer can be divided in subtypes (96, 99): 
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Pancreatic Ductal Adenocarcinoma (PDAC): PDAC causes 90% of pancreatic cancer 
cases. It originates from the cells lining the pancreatic duct and is usually malignant and 
aggressive. 
Acinar Cell Carcinoma: Acinar Cell Carcinoma is a rare form of pancreatic 
adenocarcinoma. Its tumors are characterized by excessive production of pancreatic lipase. 
Intraductal Papillary-Mucinous Neoplasm (IPMN): IPMN is a cystic tumor that grows 
from the main pancreatic duct. It appears to be benign in its early stages, but can progress 
to adenocarcinoma. 
Mucinous Cystadenocarcinoma: Mucinous Cystadenocarcinoma is a rare, malignant, 
cystic tumor that is filled with mucin. It occurs in only one area of the pancreas and is 
usually in the tail. This type of tumor is found mostly in women. 
Pancreatic Neuroendocrine Tumors (NETs): NETs are pancreatic cancer tumors that 
often release hormones into the bloodstream. They are classified as gastrinomas, 
glucagonoma, insulinomas, somatostatinomas, VIPomas, PPomas, and carcinoid tumors. 
NETs can be detected by tracking their respective hormone levels in the bloodstream. 
5.1. Pancreatic cancer staging 
The system used most often to stage pancreatic cancer is the American Joint Committee on 
Cancer (AJCC) TNM system (96, 100). This system is the first criteria applied to the 
disease and it considers: 
• The size of primary tumor (T) and whether it has spread beyond the pancreas into 
nearby organs. 
• The spread of the tumor to regional lymph nodes (N). 
• Evidence of metastasis (M) to other organs. The most common metastasis sites are 
the liver, lungs, and the peritoneum. 
5.1.1. The T categories 
• TX:  The main tumor cannot be assessed. 
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• T0:  No evidence of a primary tumor. 
• Tis:  Carcinoma in situ (the tumor is confined to the top layers of pancreatic duct 
cells). 
• T1:  The tumor has not spread beyond the pancreas and is two centimeters (cm) 
or less wide. 
• T2:  The tumor has not spread beyond the pancreas but is larger than 2 cm. 
• T3:  The tumor has spread beyond the pancreas into nearby surrounding 
structures but not into major blood vessels or nerves. 
• T4:  The tumor has spread beyond the pancreas into nearby large blood vessels 
or nerves. 
5.1.2. N categories 
• NX:  The regional lymph nodes cannot be analyzed. 
• N0:  The cancer has not spread to nearby lymph nodes. 
• N1:  The cancer has spread to nearby lymph nodes. 
5.1.3. M categories 
• M0:  The cancer has not spread to distant lymph nodes or other organs (e.g., the 
liver, lungs, or brain). 
• M1:  The cancer has spread to distant lymph nodes or other organs. 
Once the T, N, and M categories have been assessed, the information is combined to 
calculate overall stage of the pancreatic cancer (0, I, II, III, or IV). 
Stage Stage grouping Stage description 
0 Tis, N0, M0 
The tumor is confined to the top layers of pancreatic duct cells 
and has not invaded deeper tissues. It has not spread outside 
the pancreas. These tumors are sometimes referred to as 
pancreatic carcinoma in situ or pancreatic intraepithelial 
neoplasia III (PanIn III). 
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IA T1, N0, M0 
The tumor is confined to the pancreas and is 2 cm wide or 
smaller (T1). The cancer has not spread to nearby lymph nodes 
(N0) or distant sites (M0). 
IB T2, N0, M0 
The tumor is confined to the pancreas and is larger than 2 cm 
wide (T2). The cancer has not spread to nearby lymph nodes 
(N0) or distant sites (M0). 
IIA T3, N0, M0 
The tumor is growing outside the pancreas but not into major 
blood vessels or nerves (T3). The cancer has not spread to 
nearby lymph nodes (N0) or distant sites (M0). 
IIB T1-T3, N1, M0 
The tumor is either confined to the pancreas or is growing 
outside the pancreas but has not spread into major blood 
vessels or nerves (T1-T3). The cancer has spread to nearby 
lymph nodes (N1) but has not spread to distant sites (M0). 
III T4, Any N, M0 
The tumor is growing outside the pancreas and into nearby 
major blood vessels or nerves (T4). The cancer may or may not 
have spread to nearby lymph nodes (Any N). It has not spread 
to distant sites (M0). 
IV Any T, Any N, M1 The cancer has spread to distant sites (M1). 
Table 1. Pancreatic Cancer Staging. Table copied from reference (96) 
5.2. Other prognostic factors contributing to pancreatic cancer staging 
Physicians issue a prognosis that predicts the outcome of a disease based on the staging 
and the patient’s condition at the diagnosis. Several factors play a role in determining a 
prognosis, or future outcome, of pancreatic-cancer patients. Besides the staging of 
pancreatic cancer, the determination of tumor grade after a biopsy and surgery will greatly 
affect the prognosis and the chances that the patient will be cured. 
5.2.1. Tumor grading 
The tumor grade reflects how abnormal the pancreatic tumor cells appear under the 
microscope. Higher grade tumors are correlated with a poor prognosis. The scale used to 
define tumor grade goes from G1 (lowest grade; cells closely resembling natural 
morphology) to G4 (higher grade; cells are abnormal and do not resemble the natural 
morphology) (96). Microscopic cellular abnormalities include a) the presence of a highly 
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pleomorphic nucleus and basophilic cytoplasm with the presence of vacuoles; b) the 
presence of a polymorphic nucleus, more than one nucleus, or peripheral dislocation of 
cellular nucleus; and c) high frequency of mitoses (96, 101). For NET tumors, the 
proliferation marker ki67 is an added parameter to determine the tumor grade. 
5.2.2. Surgical resection margins 
Surgery still is the most favorable treatment to increase pancreatic cancer patients’ long-
term survival and cure. Depending on how much the disease has spread in a patient, surgery 
can be curative (complete tumor resection) or palliative (removal of tumor masses to 
alleviate pressure in other organs). Most patients are diagnosed in the late stage of the 
disease, and by then tumors are locally advanced or metastastic. In these cases, the tumors 
are classified as unresectable, and patients receive palliative surgery. If curative surgery is 
performed, tumors are classified as: 
• Resectable: The tumor is restricted to the pancreas or has spread just beyond the 
pancreas. In these cases, the entire tumor mass can be removed. 
• Borderline resectable: The tumor is located near blood vessels and cannot be 
completely removed, but has the potential of being completely removed. 
For patients who undergo surgery, the staging of pancreatic cancer will also consider 
whether the surgery can remove the entire tumor, or, if after removal of the tumor, there 
still is residual disease in the resection margins (96). In both cases, the margin of tumor 
resection is submitted for microscopic analysis to evaluate whether cancer cells are present. 
The margins of tumor resection are classified as: 
R0:  The tumor was completely removed and there is no microscopic indication of tumor 
cells in the resection border. 
R1:  The tumor was visibly removed, but there is microscopic indication of tumor cells 
in the resection border. 
R2:  The surgeon could not perform a complete removal of the tumor, and there is visible 
indication of large numbers of tumor cells in the resected area. 
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Patients with R0 and R1 resection margins have better prognoses than patients with R2 
margins. 
5.3. Pancreatic cancer survival rates 
There are several ways to determine a cancer patient’s chances of survival. Depending on 
the parameter used, chances of survival can be classified as: 
• The survival rate is the percentage of people diagnosed with pancreatic cancer 
who survived for a determined period of time in a determined study. Survival rate 
is not a predictor of treatment success or completion. 
• The relative survival rate is the ratio of the proportion of observed survival in a 
cohort of cancer patients to the proportion of expected survival in a comparable 
cohort of cancer-free patients. 
• Median survival is the amount of time that 50% of pancreatic cancer patients have 
died and 50% have survived. 
• Overall Survival (OS) the amount of time between the cancer diagnosis or 
beginning of a treatment to the patient’s death. OS is often used in clinical trials as 
an indication of how well a treatment works. 
• Progression free survival (PFS) is the amount of time between the beginning of 
treatment to disease progression or the patient’s death. PFS is used to evaluate the 
effectiveness of drugs in clinical trials. 
• Disease free survival is the amount of time between the end of treatment to when 
the patient starts to show signs of disease progression or has died. 
For all combined stages of pancreatic cancer, the current one-year relative survival rate is 
20%, and the five-year rate is 6% (95, 96, 102). Advanced stage and spreading of the 
disease by the time of diagnosis are the main contributors to these poor survival rates. By 
the time of diagnosis, less than 20% of patients are eligible for surgery, which is the most 
effective treatment for the disease. In cases where surgery can be performed, the average 
survival period is 23–36 months, and the overall five-year survival rate is about 10%. But 
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if the tumor can be completely removed and there is no sign that the cancer has spread, the 
five-year survival rate is reported to be 20–35% (102). 
5.4. Pancreatic cancer mutations 
Current knowledge about pancreatic carcinogenesis suggests that multifocal, microscopic 
pancreatic intraepithelial neoplasms (PanINs), intraductal papillary mucinous neoplasms 
(IPMNs), and mucinous cystic neoplasms (MCNs) are precursor lesions for pancreatic-
cancer formation (103-105). PanINs, IPMNs, and MCNs are usually asymptomatic and the 
progression of these lesions into malignant pancreatic cancer is outlined in Figure 2. The 
most predominant and well-studied precursor lesion that precedes pancreatic ductal 
adenocarcinoma (PDAC) is PanINs. PanINs are noninvasive, asymptomatic, and 
microscopic lesions (usually <5 mm) that are comprised of columnar or cuboidal cells with 
varying degrees of cytological dysmorphia. PanINs are usually classified as 1) PanINs A 
and B—low-grade lesions with lower levels of cellular atypia; 2) PanINs-2—intermediate 
grade lesions with mild to moderate levels of cellular atypia; and 3) PanINs-3 or high grade 
PanINs, which show a high degree of cellular atypia and are usually referred as “carcinoma 
in situ”. 
 22 
 
Figure 2 Pancreatic Cancer Precursor Lesions. Progression of precursors legions that lead to 
transformation and carcinogenesis of a normal pancreas. (Figure extracted from reference (105)). 
One of the main driving forces in converting PanINs to invasive PDACs is the activation 
of the small GTPase protein KRAS. KRAS alternates between two states: the GTP-bound 
active and GDP-bound inactive. The guanine nucleotide exchange factors (GEFs) are 
responsible for activating KRAS by exchanging GDP for GTP, and the GTPase-activating 
proteins (GAPs) inactivate KRAS by hydrolyzing the GTP to GDP (106). 
In humans, point mutations at the KRAS codons G12 (exon 2), G13 (exon 2), and Q61 
(exon 4) are activating mutations that impair the intrinsic activity of GAPs to hydrolyze 
GTP to GDP, which, in turn, activating cell proliferation. Mutations in codon G12 are most 
prevalent in PDACs present in 98% of all KRAS mutations in PDAC. The mutation occurs 
in codon 12 (GGT-GAT) and results in a single amino-acid change from glycine (G) to 
aspartic acid (D), which makes KRAS constantly bound to GTP and in a constant activated 
state (106, 107). Constitutively activated KRAS activates pro-carcinogenic pathways such 
as Raf/Mek/Erk, PI3K/Pdk1/Akt, and the Ral guanine nucleotide exchange factor (108, 
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109). Unregulated stimulation of these pathways results in sustained proliferation and 
survival of cancer cells; metabolic reprogramming; remodeling of the tumor 
microenvironment; evasion of the immune response; and increased cell migration and 
metastasis. All these effects are hallmarks of cancer and contribute to the progression of 
PanINs to invasive PDAC (106). In fact, KRAS mutations can be found as early as in 
PanINs-1A. After KRAS activation, cancer cells undergo enhanced genomic instability, 
which leads to loss of functioning in tumor suppressors P53 (70 % of PDACs), P16 (98% 
of PDACs), SMAD4 (50% of PDACs), and BRCA1 and BRCA2 (6.6 % of PDACs) (107, 
110-114). 
5.5. Type I IFN pathway in pancreatic cancer cells 
Besides modulating the immune response against pathogens, stimulation of the type I IFN 
pathway leads to the expression of Interferon Activated Response Elements (ISRE) and 
later expression of anti-viral genes such as PKR, MX1, OAS, TRIM5, ZAP, APOBEC3G, 
EPSTI1, XAF1, GBP, and IFITM3 (115). During viral infection, these genes are 
responsible for stopping viral replication in infected cells and halting the spread of the 
infection to neighboring cells. Pancreatic cancer cells have defective type I IFN pathways 
(116, 117) and, therefore, are susceptible to viral infection. The susceptibility of PDAC 
cells to viral infection has been connected with the lack of MX1, EPSTI1, XAF1, and GBP1 
IFN inducible anti-viral genes (118), but not all PDAC cells have disrupted type I IFN 
pathways (117). Despite an active IFN-induced anti-viral response in some PDAC cells 
(117, 119), this response does not impede adenovirus replication in these cells (24, 56, 
120). Even though the type I IFN pathway might not be completely disrupted in some 
pancreatic cancer cells, the adenovirus is inheritably resistant to the anti-viral effects 
caused by IFN. As mentioned above, the expression of VA-RNA by the adenovirus 
promotes preferential viral RNA translation in cells with active PKR that are stimulated by 
IFN (117, 119).  
Type I IFN induces higher expression of MHC-I on the cell surface, thereby increasing the 
presentation of viral-specific peptides to cytotoxic CD8+ lymphocytes (CTL), which then 
leads to the increased elimination by the lymphocytes of virally infected cells. The 
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adenovirus’s E3 gp19K protein inhibits the loading of MHC-I with cellular peptides or the 
transport of loaded MHC-I to the cell surface, which avoids the CTLs’ elimination of 
infected cells (121, 122).  
Adenovirus E3 gp19K also can suppress infected cell recognition by natural killer (NK) 
cells by performing intracellular sequestration of stress-induced MHC-I chains A and B, 
which are part of the complex of receptors recognized by NK cells (123). Despite 
adenovirus ability to suppress recognition by natural killer cells, Aoki and colleagues have 
shown that an IFN-expressing adenovirus still could stimulate a NK response against 
pancreatic cancer tumors leading to tumor reduction in adenovirus untreated tumors even 
though virus had the capacity of evade the NK response against infected cells (119).  
5.6. Use of Oncolytic Adenoviruses to treat pancreatic cancer 
There are several cases where oncolytic adenoviruses or CRADs have been employed in 
clinical trials as therapy against PDAC. ONXY-015 (dl1520) was the first replication-
competent oncolytic adenovirus used in clinical trials to treat PDAC (124). ONYX-015 
was designed to selectively replicate in pancreatic-cancer cells by deleting the E1B 55 kD 
protein, which inhibits the function of tumor suppressor p53. Although the use of ONXY-
015 reduced PDAC tumor size in PDAC pre-clinical models (125), the effectiveness of 
ONXY-015 to treat PDAC was not significant even when the virus was combined with 
gemcitabine (32). While the virus was injected in primary PDAC tumors, there was no 
proof of viral replication in tumors, and patients developed high levels of neutralizing 
antibodies (126). The virus’s lack of replication in PDAC tumors could be explained by 
the fact the PDAC cells express low levels of CAR receptors. As ONXY-015 is based on 
the adenovirus type 5, which uses CAR to infect cells, it is possible that the virus did not 
achieve high infectivity in PDAC. Despite that, ONXY-015 was approved as a therapy to 
treat head and neck cancer in China (33).  
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5.7. Treatment of Pancreatic cancer 
5.7.1. Surgery 
In cases where surgery can be performed on PDAC patients, surgery procedures can be 
described as: 
• The Whipple procedure (pancreaticoduodenectomy) is the most common 
operation performed on patients. During this operation, the surgeon removes the 
head of the pancreas and sometimes the body as well. The surgeon may also elect 
to remove nearby structures such as parts of the small intestine, bile duct, stomach, 
gallbladder, and lymph nodes near the pancreas. 
• Distal pancreatectomy consists of removing only the tail of the pancreas. 
• Total pancreatectomy which is the complete removal of the pancreas. 
5.7.2.  Standard of care 
For many years, the approved standard of care to treat PDAC was gemcitabine as a 
monotherapy (127). But in January of 2017, the approved standard of care was changed to 
Gemcitabine plus Capecitabine. Although treatment with Gemcitabine-based therapies 
were never proven to extend the long-term survival of patients, treatment with Gemcitabine 
plus Capecitabine resulted in an overall survival period of 28.8 months, while treatment 
with gemcitabine alone extended the survival period to only 25 months. For this reason, 
the standard of care changed to the use of Gemcitabine plus Capecitabine (128).  
Despite an already-approved standard of care to treat PDAC, several therapeutic protocols 
are being tested in PDAC clinical trials. Though many of these protocols have failed to 
improve survival periods of PDAC patients, adjuvant therapies using FOLFIRINOX, nab-
paclitaxel combined with Gemcitabine, and IFN-alpha combined with chemoradiation 
have shown promising results. Adjuvant therapy is a form of treatment where surgery is 
performed before treatment with other therapeutic agents such as chemotherapy or 
radiation. 
 26 
5.7.3. FOLFIRINOX and nab-paclitaxel plus Gemcitabine in adjuvant PDAC 
therapy 
Clinical trials that have tested the use of FOLFIRINOX (Folinic acid, Irinotecan, 
Fluorouracil, and Oxaliplatin) in an adjuvant setting have shown that the therapy improved 
short-term survival of PDAC patients compared to treatment with gemcitabine alone (129, 
130). Despite its apparent effectiveness, however, FOLFIRINOX is highly toxic and 
tolerated by only younger patients (130, 131). Clinical trials that assessed the effectiveness 
of adjuvant therapy and treatment with nab-paclitaxel plus Gemcitabine also showed 
improved patient survival compared to use of Gemcitabine alone. While effective, the 
survival of patients who were treated with nab-paclitaxel plus Gemcitabine was not 
different than the survival of patients treated with FOLFIRINOX. Furthermore, treatment 
with nab-paclitaxel (albumin bound paclitaxel) plus Gemcitabine was also extremely toxic 
to patients, and long-term survival was not improved by using neither nab-paclitaxel plus 
Gemcitabine nor FOLFIRINOX in therapy (132, 133). 
5.7.4. IFN-a combined with chemotherapy and radiation in adjuvant PDAC therapy 
(IFN-therapy) 
Phase II clinical trials where patients were treated with adjuvant therapy and subcutaneous 
IFN-α (IFN) combined with radiation, 5-FU, and Cisplatin reported an increase in the two-
year survival of patients by 16–40% (134-136), and an increase in their five-year survival 
by 35% (134, 137, 138). Another Phase II trial that added Gemcitabine to the same 
treatment protocol reported 55% and 26% increase in the one and two-year survival of 
patients respectively (136). Most therapies to treat PDAC such as FOLFIRINOX, nab-
paclitaxel plus Gemcitabine, and even Gemcitabine plus Capecitabine showed 
improvement in only the patients’ short-term survival rates. To date, IFN-therapy is one of 
the few therapeutic regimens that can show an impressive increase in patients’ long-term 
survival. While trial results have been encouraging, strong IFN systemic toxicity and low 
levels of cytokine in tumors were identified as the therapy’s main drawbacks (139-141). 
Most of the effects of IFN toxicity included extreme fatigue, leucopenia, severe 
thrombocytopenia, flu like-symptoms, and gastrointestinal disturbances. Although 
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seemingly benign, the toxicity effects were rated as grade III and IV, and most patients that 
displayed IFN toxicity had to be hospitalized and dropped out of the trials (135, 137, 142-
144).  
IFN-a (IFN) is a cytokine secreted mainly by lymphocytes (NK cells, B cells, and T cells), 
macrophages, and fibroblasts. Besides inducing an anti-viral state in infected cells and 
having immunostimulatory properties, IFN has several anti-cancer therapeutic properties. 
The cytokine is known to inhibit proliferation, induce apoptosis, reduce angiogenesis, and 
potentiate the killing effect of chemotherapy and radiation in cancer cells (139). Because 
IFN was reported to have a high degradation rate in the blood of patients during treatment, 
low levels of the cytokine in tumors constituted one of the major setbacks to IFN-therapy 
efficacy (139-141). Despite the reported IFN systemic toxicity and lower IFN levels in 
tumors, use of IFN in combination with chemoradiation in an adjuvant setting still is one 
of the most promising therapeutic regimens to treat PDAC. In addition to contributing to 
longer patient survival, a multicenter Phase III clinical trial showed that patients who were 
treated with IFN-therapy developed a cancer-specific immune response (137, 144). 
Although no correlation was found between increased survival and the development of an 
anti-tumor immune response in that trial, long term follow-up of phase II clinical trials 
developed by the Virginia Manson group showed that 28% of the patients survived for at 
least 10 years. Of these patients, nine lived more than ten years and seven are still alive 
without any indication of disease (145). Because the development of an anti-tumor immune 
response is known to reduce tumor recurrence and improve patients’ long-term survival, it 
is possible that stimulation of anti-tumor immune response played a role in helping these 
patients experience extended survival periods after being treated with the IFN therapy. 
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6. Mechanism of action of therapeutics used in IFN therapy 
6.1. Ionizing radiation 
Ionizing radiation is the most commonly used form of radiation given to patients during 
cancer therapy. X-rays and gamma rays are the most often used types of electromagnetic 
ionizing radiation in cancer treatment (146). X-rays are produced by the high-energy 
acceleration of electrons followed by the abrupt stop of those electrons in a tungsten or 
gold surface that results in a release of energy. X-rays have a short wavelength and their 
delivered energy can be classified as “packages of energy,” or photons. One photon carries 
124 KeV of energy, which is enough to break chemical bonds between molecules. The 
potency of X-rays is mostly a function of the size of the photons, not the amount of energy 
absorbed (147).  
Gamma-rays are penetrating electromagnetic radiation that is derived from the radioactive 
decay of atomic nuclei. During nuclear decay, radiation—comprised of alpha-particles, 
beta-particles, and neutrinos—is emitted. The delivery of energy also forms photons, which 
are part of the highest observed range of photon energy (146). While X-ray energy ranges 
from 100eV–124KeV, gamma-ray energy is greater than 100 KeV. Although gamma-ray 
photons are more likely to cause biological changes compared to X-rays, X-ray energy can 
also cause extensive damage to DNA and cellular structures.  
The biological effectiveness of radiation depends on the linear energy transfer (LET), total 
dose, fractionation, and radiosensitivity of the cells to radiation treatment (148). Radiation 
particles are either negatively charged (electrons), or positively charged (protons, alpha 
rays, and other heavy ions) and both can deposit high amounts of energy on the targeted 
areas causing accentuated cellular damage. The potent cellular damage caused by these 
particles results from their capacity to transfer energy right after they pass though matter 
(146). 
Radiation is classified as either directly or indirectly ionizing. X-rays and gamma rays are 
considered directly ionizing if they transfer energy and disrupt the atomic structure in cells 
causing chemical and biological changes. During radiotherapy, which uses a linear 
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accelerator, the indirectly ionizing effect—or the Compton process—predominates. In this 
process, the energy photon interacts with a free electron that absorbs the energy photon and 
is ejected from its orbital path. The remaining non-absorbed energy is then deflected with 
less energy to the surrounding areas. During radiation, several fast-moving electrons are 
produced, and they are responsible for the biological indirect effect of radiation by breaking 
chemical bonds, damaging cellular structures, interacting with other compounds (e.g., 
water), and causing DNA damage (147). Emitted photons can also ionize water molecules, 
and, as a result, high levels of free oxoniumyl radicals (H2O+) are formed.  These ion 
radicals have an unpaired electron in their outer shell, which makes them react to DNA 
bases causing extensive damage. Radiation-induced DNA damage can cause single-strand 
break (SSB), base damage, and double-strand break (DSB) in cancer cells. Because cancer 
cells highly depend on DNA replication, DSB has the most deleterious effect on cells and 
results in cell apoptosis (146, 147). 
6.2. Radiation in IFN therapy 
In IFN-based clinical trials, patients were given radiation in a fractionated manner. Patients 
received 45–54 Gray (Gy) in 25 fractions of approximately 1.8–2Gy five days a week for 
five–six weeks (134, 135, 149). The concept of fractionated radiation takes into 
consideration the 4Rs: repair, redistribution, reoxygenation, and repopulation (147).  
Repair Phase 
Radiation can cause potentially lethal damage (PLD), sub-lethal damage (SLD), and lethal 
damage (LD) to cellular DNA. When radiation is fractionated during a treatment period, 
PLD and SLD mainly accumulate in cellular DNA. To efficiently repair this damage, cells 
need to activate DNA-repair pathways and induce cell-cycle arrest. Because cancer cells 
often have mutations in their DNA-repair pathways, and lack important tumor-suppressor 
genes (e.g., TP53, p16, and BRCA genes), they are unable to undergo cell-cycle arrest and 
cannot efficiently repair the DNA damage. Consequently, the administration of fractionated 
radiation results in the extended accumulation of non-repaired DNA damage in cells that 
leads to mitotic crisis and cell apoptosis. This is the repair phase of fractionated radiation. 
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Redistribution Process 
Cells are most sensitive to radiation DNA damage when they are in the G2/M phase of the 
cell cycle, and are particularly resistant to damage when they are in the S-phase of the 
cycle. During radiation, some cells are G2/M phase and others are in the S-phase. The 
fractionation of radiation allows the cells that are in the S-phase of the cell cycle to have 
time to progress to G2/M stage and be susceptible to radiation damage. This happens during 
the radiation interval—the 24-hour interval between successive administrations of 
fractionated-radiation doses. This is the redistribution process, and its goal is to increase 
the cell population that can be affected by radiation. 
Reoxygenation Process 
Oxygen is a potent inducer of DNA damage during radiation because of the formation of 
free radicals. Free radicals can cause extensive DNA damage and also disrupt cell 
structures which results in apoptosis. There is a gradient distribution of oxygen in tumors, 
meaning that the borders of the tumors are more oxygenated than their internal parts. 
Between the border of a tumor and its center there is a gradual decrease in oxygen 
concentration, and the center is most of the time hypoxic. A tumor can also go through an 
acute hypoxic stage (when its capillaries momentarily close and do not provide oxygenated 
blood) and can also experience a chronic stage of hypoxia (where oxygenated blood does 
not reach the center of the tumor because of inefficient vascularization). By spacing the 
radiation doses, there is the possibility that transiently closed vessels can reopen and 
provide oxygen to hypoxic cells increases. Radiation kills cells that are near capillaries 
more effectively, relieving the capillary pressure and allowing a flow of oxygenated blood 
to the more-internal parts of the tumor. As these cells are destroyed, the pressure on nearby 
capillaries is relieved, and oxygenated blood can irrigate the tumor’s hypoxic areas more 
efficiently making these cells susceptible to free oxygen species formation during 
radiation. This is the reoxygenation process. 
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Repopulation Process 
After radiation, cancer cells can undergo a high rate of cell growth and quickly repopulate 
the tumor. But, highly replicating cells are especially sensitive to radiation, which can 
enhance the efficacy of fractionation radiation in eliminating these cells. Because the 
fractionation of radiation is given over a period of time, most of cells that have the capacity 
of repopulating the tumor are affected leading to the inability of these cells to contribute to 
increase in tumor volume. This is the repopulation process (147, 150). 
7. Chemotherapies used in IFN-therapy 
7.1. 5-FU, Gemcitabine, and Cisplatin chemotherapies 
During the five to six weeks of radiation in the IFN-based clinical trials, chemotherapy 
treatment consisted of the administration of a bolus dose of Cisplatin at the beginning of 
the week, subcutaneous IFN three times during the week, and continuous administration of 
5-FU. After a period of rest, patients then received continuous doses of 5-FU or, depending 
on the clinical trial in question, Gemcitabine for additional four weeks(135, 136). All these 
chemotherapy drugs are considered DNA-damaging drugs since 5-FU and Gemcitabine 
are base analogs and Cisplatin can bind to nucleophilic groups in DNA hampering DNA 
replication and repair.  Using these drugs in conjunction with radiation attempts to 
maximize deleterious DNA damage in cancer cells. 
7.2. Fluorouracil (5-FU) 
5-Fluoro-Uracil (5-FU) is a fluoropyrimidine or a fluorinated base analog of uracil with a 
fluorine atom at the C-5 position instead of a hydrogen (Figure 3) (151, 152). 5-FU enters 
cells through the same facilitated-transport mechanism as uracil, and is converted into 
several active metabolites: fluorodeoxyuridine monophosphate (FdUMP), 
fluorodeoxyuridine triphosphate (FdUTP), and fluorouridine triphosphate (FUTP). These 
metabolites are responsible for the biological activity of 5-FU in cells, which includes 
inhibiting thymine production by the enzyme thymidylate synthase (TS), and interfering 
with DNA and RNA functions (152). Inactivation of 5-FU happens in the liver where 
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dihydropyrimidine dehydrogenase (DPD) converts 5-FU to its inactive form 
dihydrofluorouracil (DHFU). 
7.2.1. 5-FU inhibition of thymidylate synthase and DNA damage 
Normally, thymidylate synthase (TS) catalyzes the reductive methylation of deoxyuridine 
monophosphate (dUMP) into deoxythymidine monophosphate (dTMP) using reduced 
folate (CH2 THF) as a methyl donor. dTMP is the source to produce de novo thymidylate, 
which is used to produce thymine in cells. Thymine is used in DNA repair and newly 
formed DNA molecules. To catalyze this reaction, TS forms a ternary complex with the 
nucleotide dUMP and CH2 THF, but when FdUMP is present, the 5-FU metabolite forms a 
stable ternary complex with the TS nucleotide binding site and with reduced folate blocking 
the access of dUMP to the TS and inhibiting thymidylate (dTMP) production. This leads 
to thymine deprivation in cells, which, in turn, prevents the synthesis of new DNA 
molecules and DNA repair. Because cancer cells are highly dependent on DNA synthesis 
to support their growth, and are most of the time unable to induce cell cycle arrest due to 
the lack of tumor suppressor genes, 5-FU treatment causes cells to undergo mitosis crisis 
and apoptosis (151, 152).  
In addition, the depletion of dTMP caused by TS inhibition results in the reduction of 
deoxythymidine triphosphate (dTTP) and perturbation in the levels of deoxynucleotides 
dATP, dGTP, and dCTP. Deoxynucleotide imbalances can disrupt DNA synthesis and 
repair, resulting in lethal DNA damage. When a deoxynucleotide imbalance occurs, dUMP 
also accumulates in cells, which leads to higher conversion of deoxyuridine triphosphate 
(dUTP). A high ratio of dUMP/dUTP makes nucleotide excision DNA repair inefficient, 
and results in increased incorporation of false-nucleotide bases (5-fluoronucleotides) in 
DNA. The many cycles of misincorporation, inefficient base-excision repair, and DNA-
repair inhibition results in DNA strand breaks and cell death. 
7.2.2. 5-FU impact on RNA 
The 5-FU metabolite 5-FUTP is extensively incorporated into RNA and it disrupts normal 
RNA processing and function. 5-FUTP misincorporation inhibits the conversion of pre-
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RNA into mature rRNA, disrupts the post-transcriptional modification of tRNA, the 
assembly and activity of snRNA/protein complexes, and inhibits the splicing of pre-RNA 
(152-155). 5-FU metabolites also inhibit the post-transcriptional conversion of uridine to 
pseudouridine impacting RNA, rRNA, tRNA, and snRNA because each of these RNA 
molecules require pseudouridine. Finally, 5-FU also interferes with RNA processing and 
function by inhibiting the polyadenylation of mRNA, which significantly interferes with 
its function (156, 157). It is not known whether 5-FU interference with DNA is stronger 
than its interference with RNA. But it is possible that both effects contribute to cell death. 
Despite this uncertainty, it is possible that using 5-FU in combination with other DNA-
damaging drugs might result in more pronounced negative effects in DNA, making DNA 
damage in treatments with 5-FU the main cause of cancer-cell death. 
 
Figure 3. Drawing made using Chemspider (http://www.chemspider.com/). Figure adapted 
from reference 132. 
7.3. Cisplatin (CDDP) 
Cisplatin (CDDP) is a divalent, inorganic, water soluble, platinum-containing complex that 
is highly reactive to nucleophilic groups present in the cellular DNA (158). The drug is 
transported through the cellular membrane by passive diffusion, and becomes activated 
when cis-chloro ligands are replaced by water molecules (Figure 4). This replacement 
process forms an aquated form of CDDP that is trapped intracellularly. Activated CDDP is 
a highly reactive species and shows high avidity for nucleophilic groups in the cell (159, 
160). The interaction between CDDP and cytosolic nucleophilic groups in glutathione 
(GSH), methionine, metallothionein, and proteins can inactivate CDDP. If this step is not 
a rate limiting process, activated CDDP reaches the nucleus, and interacts with nucleophilic 
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groups in DNA and nuclear proteins (161). In the nucleus, CDDP reacts with the 
nucleophilic N7-sites of purine bases in the cellular DNA and causes intra- and inter-strand 
cross-linkage of purine bases (159, 160). Relatively speaking, intra-strand cross-linkages 
are the most cytotoxic lesions and are highly correlated with increased apoptosis (162, 
163). The interaction between CDDP and DNA causes distortions in the DNA strand and 
attracts proteins that recognize DNA damage. These damage-recognition proteins include 
the hMSH2 or hMutSa proteins, which are components of the mismatch-repair (MMR) 
complex. The interaction between CDDP and DNA also attracts non-histone chromosomal 
high-mobility proteins (HMG1 and HMG2), RNA polymerase I binding factor (hUBF), 
and TATA binding protein (TBP) transcription factors. When CDDP–DNA adducts 
extensively accumulate in the cell, the cell up-regulates p53 and undergoes cell-cycle arrest 
(159). As mentioned above, cancer cells have a mutated p53 or lack this tumor-suppressor 
protein. Thus, these cells are unable to induce cell cycle arrest and start DNA repair. Thus, 
there is accumulation of CDDP–DNA adducts in cells leading to mitosis crisis and 
apoptosis.   
 
Figure 4. Cisplatin and its activated aquated form. 
7.4. Gemcitabine 
Gemcitabine (2',2'-difluoro-2'-deoxycytidine, or dFdC) is a nucleoside analog of 
deoxycytidine (Figure 5). It is derived from the drug cytosine arabinoside (Ara-C), which 
was classically used as a chemotherapy drug for acute myeloid leukemia, acute 
lymphocytic leukemia, chronic myelogenous leukemia, and non-Hodgkin's lymphoma 
(164, 165). Gemcitabine is a pro-drug, and, once it is transported into a cell through 
nucleoside transporters, it is phosphorylated by deoxycytidine kinase (dCK) into 
gemcitabine monophosphate (dFdCMP) and dFdCMP and is then converted into 
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gemcitabine di- and triphosphates (dFdCDP and dFdCTP). dFdCDP and dFdCTP are 
Gemcitabine’s active metabolites (165) and they perform several inhibitory functions in 
cells.  
The dFdCTP metabolite inhibits DNA polymerase and is incorporated into DNA. 
Incorporation of this metabolite into DNA results in chain-elongation termination and 
prevents DNA damage repair by DNA repair enzymes (166, 167). dFdC and dFdCTP may 
also be incorporated into RNA, although the effects of the incorporation in RNA are unclear 
(165). These gemcitabine metabolites also induce self-potentiation of Gemcitabine in cells 
(168). They prolong the maintenance of high intracellular concentrations of gemcitabine 
metabolites and increase the probability of their successful incorporation into nucleic acids, 
mainly DNA. This process occurs by reducing the competition between the cell’s natural 
nucleic acid related metabolites and the gemcitabine metabolites. The dFdCDP metabolite, 
for example, inhibits the enzyme ribonucleotide reductase (RR) (169, 170), while the other 
metabolites can inhibit the enzymes cytidine triphosphate synthetase (CTP synthetase) 
(171) and deoxycytidylate deaminase (dCMP deaminase). These inhibitory processes 
decrease the competing deoxyribonucleotide pools necessary for DNA synthesis (171, 
172). Finally, gemcitabine can inhibit topoisomerase I, leading to topoisomerase I-
mediated DNA break formation, which significantly contributes to the drug’s cytotoxicity 
(173). Apoptosis is the main mechanism of cancer-cell death caused by gemcitabine (174, 
175). Apoptosis occurs because cancer cells cannot induce cell-cycle arrest, mobilize DNA 
repair pathways, and produce deoxynucleotides for DNA synthesis. 
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Figure 5. Structures of deoxycytidine, Cytosine arabinose (Ara-C), and Gemcitabine. Figure 
from reference (176). 
7.5. IFN-a 
Interferon alpha (IFN) is a pleiotropic cytokine that can induce negative regulatory effects 
on the growth of normal and malignant cells in vitro and in vivo (152, 177). As mentioned 
above, IFN has therapeutic properties that can be used in cancer treatment. Some of these 
therapeutic properties include 
• Direct anti-proliferative effects in cancer cells by prolonging cell-cycle completion;  
• Induction of genes that cause RNA degradation;  
• Inhibition of protein synthesis;  
• Down-regulation of oncogene expression;  
• Induction of tumor-suppressor genes;  
• Antagonism of epidermal growth factor (EGF) and platelet-derived growth factor 
(PDGF); 
• Downregulation of cell-surface receptors for growth factors;  
• Inhibition of tumor neovascularization by downregulation of vascular endothelial 
growth factor (VEGF); 
• Basic fibroblast growth factor; and 
• Matrix metalloproteinase-9 (178-183).  
IFN is also a radiosensitizer and was used in several clinical trials in conjunction with 
radiation (142, 143, 184). It also is a chemosesnitizer to 5-FU, Cisplatin, and Gemcitabine 
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(183). In the case of 5-FU, IFN can synergistically potentiate 5-FU’s cytotoxic effect by 
potentiating single- and double-stranded DNA breaks in cancer cells by boosting the 
misincorporation of 5-fluoropyrimidides (FdUTPs) to DNA (152, 177, 185-187).  
With regard to the stimulation of an anti-tumor immune response, IFN can enhance the 
immunogenicity of tumors. IFN increases the expression of MHC-I in tumor cells; induce 
the differentiation, maturation, and function of dendritic cells (DC); enhance the survival 
of T cells; stimulate the generation of CD8+ memory cells; enhance macrophage activity; 
and activate natural killer cells (179, 188-190). 
8. Effect of chemotherapy in replication of oncolytic vectors 
Several treatments are based on using chemotherapy in combination with oncolytic viral 
vectors (191). Although these treatments have been effective, there still is a question 
whether chemotherapies can affect viral replication in cells. Studies that have explored the 
inhibition of chemotherapies to oncolytic vectors have found that administering 5-FU, 
irinotecan (CPT-11), or methotrexate (MTX) in combination with Herpes simplex virus 1 
(HSV-1), and use of 5-FU combined with rinderpest virus (RPV) reduced viral replication 
in cancer cells (191, 192). Despite these findings, using chemotherapies 1716 and 
Mitomicyn C (MMC) in combination with HSV resulted in synergistic combinations and 
had no effect on viral replication in lung-cancer cells (193). When HSV is used in 
virotherapy, the vectors are modified to exclude its virulence factors (e.g., viral 
ribonucleotide reductase (RR) and γ34.5, which induce E2F release in cells). As a result, 
selective replication of modified HSV occurs in cancer cells because these cells usually 
express homologs of these virulence factors or have high levels of free E2F. As treatment 
of cancer cells with chemotherapy can upregulate expression of these HSV virulence factor 
homologs in cells, in these cases, using chemotherapies in combination with HSV can 
actually enhance viral replication in infected cells (191). 
Use of the oncolytic adenovirus vector (OAd) ONYX-015 in combination with Cisplatin 
(CDDP) or 5-FU was shown to enhance an anti-tumor response in carcinoma cells (194). 
Also, a Phase II clinical trial for head-and-neck cancer showed that combining CDDP and 
5-FU with ONYX-015 is effective (195). ONYX-015 was also clinically tested in 
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combination with 5-FU and folinic acid (leucovorin) (196), MAP chemotherapy (i.e., 
mitomycin C [MMC], doxorubicin [Adriamycin; ADR], and CDDP) (197), irinotecan, 5-
FU (198), and gemcitabine (32) showing to be effective in some treatments. In these cases, 
ONYX-015 by itself did not produce an objective anti-tumor response in all treated tumors, 
but marked anti-tumor response was observed in some cases, especially when 
chemotherapy alone had previously failed in the patient (199). In contrast, combinations of 
5-fluorouracil (5-FU) and oncolytic adenoviruses vectors (OAds) have been shown to 
inhibit viral replication in pancreatic cancer cells (200). 
9. Study of the Combination Index between therapeutic agents 
Cancer can be treated in several ways, and treatments usually gravitate towards surgery, 
chemotherapy, radiation, and, most recently, immunotherapy and gene therapy. Whatever 
the treatment method, it usually is not limited to a single therapy (monotherapy). Except 
for curative resection through surgery, treatments usually consist of combination therapy, 
that is, a combination of two or more nonsurgical therapeutic methods. As discussed above, 
adjuvant combination therapy consists of surgery followed by chemotherapy, radiation, 
immunotherapy, gene therapy, or even a combination of two or more of these therapeutic 
modalities. Neo-adjuvant combination therapy starts with treatment using nonsurgical 
therapeutic modalities (e.g., chemotherapy, radiation, immunotherapy, and others) 
followed by surgery. This method is usually employed when the tumor size needs to be 
reduced before surgery can be performed. 
Because each therapeutic approach has a specific mechanism of action, multiple drugs can 
attack different targets in a single cell. And since tumors are formed by multiple 
subpopulations of heterogeneous cells—each one being in a different mitotic stage or 
presenting a different level of drug resistance—combining drugs with different 
mechanisms of action can result in more effective cancer treatment. In IFN therapy, for 
example, DNA-damaging agents such as CDDP and 5-FU are combined with radiation, 
which is also DNA damaging. All these therapeutic agents can cause DNA damage in a 
different manner, and when they are combined with IFN-a, there is a potentiation of their 
DNA damaging effects by the chemoradiosensitization properties of IFN.   
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Today, however, combining therapeutic agents is not done randomly. Combination 
treatment usually considers the drugs’ individual mechanisms of action and their collective 
interaction to kill cancer cells. A drug interaction can be synergistic, additive, or 
antagonistic. A synergistic interaction occurs when combining two drugs results in a more 
potent effect compared to the individual effect of each drug. In cases of synergistic 
interaction, it is possible to replicate or potentiate the level of a therapy by using a lower 
dose of each drug in combination. Synergism is highly desirable for cancer therapy because 
it can more efficiently eliminate cancer cells using lower doses of each therapeutic 
component, which will also reduce the therapy’s toxicity. An additive effect occurs when 
combining two drugs results in an effect equivalent to the sum of the individual effects of 
each drug. Finally, an antagonistic effect occurs when combining two drugs decreases the 
individual effects of each drug. Calculating the Combination Index (CI) between drugs 
can determine how they will interact. 
9.1. Isobologram 
S. Loewe developed the isobologram in 1927 (201), and this is a commonly used method 
to determine the drug-combination index. Following Loewe’s work, Grabovsky and 
Tallarida are now studying and further developing the isobologram concept (202-204). 
Although their method is efficient, it allows only for the determination of the CI between 
two drugs. The effectiveness of the method, therefore, is necessarily limited in cases of 
multiple drug therapies—such as IFN therapy—since it cannot determine the CI for 
combinations of more than two drugs. As discussed above, IFN therapy concomitantly uses 
two chemotherapy drugs in combination with IFN and radiation.  
The isobologram assumes that all drugs used in combination have a constant relative 
potency, which means that at any effect level the equally effective doses (a of Drug A 
and b of Drug B) show a constant-dose ratio: a/b = R(203). The isobologram’s graphical 
representation displays the linear relationship (isobole) between two drugs. In the graph 
below, for example, each drug and its respective concentrations are displayed in either the 
x or y axis, and the linear relationship between them signifies the point where the two drugs 
have an equivalent magnitude of effect (203, 204). Combinations of different drug doses 
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can lie below the isobole (synergistic), on it (additive), or above it (antagonistic) (Figure 
6). 
 
Figure 6. Isobologram graphical representation. 
One drawback of using isobolograms is that, when drugs show a variable relative potency, 
it results in the representation of a nonlinear isobole of additivity instead of a linear isobole. 
In such a case, experimental results could be mistaken for synergism or antagonism. 
Despite this possible limitation, using isobolograms in analyzing the Combination Index is 
not incorrect. Several published articles address this limitation and propose ways to analyze 
data despite this apparent pitfall (202, 203). 
9.2. Chou–Talalay method of combination analysis 
The Chou– Talalay method of combination analysis, which Chou and Talalay developed in 
1974, is a more advanced method of analyzing drug combinations because it can determine 
the Combination Index between two or more drugs. Combination analysis is performed 
using the Median–Effect Equation (MEE) of the mass-action law , which was developed 
by Chou-Talalay in 1974 through the derivation of more than 300 rate equations of enzyme 
dynamics, followed by mathematical induction and deduction (Figure 7) (205). The MEE 
equation developed by Chou represents the “unified theory” of the four basic equations:  
(a) the Michaelis–Menten equation, which described the rate of enzyme kinetics; (b) the 
Hill equation, which determines ligand binding saturation; (c) the Henderson–Hasselbalch 
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equation, which describes the derivation of pH as a measure of acidity; and (d) the 
Scatchard equation, which results in the Scatchard plot for analysis of receptor bound and 
unbound ligands (205-209). Although these four equations have different physicochemical 
meanings, they share the same mathematical form (the MEE equation). That is why the 
MEE equation is called the “unified theory” (Figure 7).   
 
Figure 7. Representation of the Median-Effect Equation (MEE) and its derivations. Figure 7 
is extracted from reference (205). The rearrangement of the MEE equation (or taking its logarithmic 
form) results in the Michaelis–Menten, Hill, Henderson–Hasselbalch, and Scatchard equations. In 
the MEE, (fa) is the fraction of affected; (fu) is the fraction of unaffected; (D) is the dose of the drug; 
(Dm) is the median-effect dose or potency of the drug; and m is the sigmodicity (shape) of the dose-
effect curve (m=1, hyperbolic; m>1, sigmoidal; and m <1, flat sigmoidal). 
The MEE was used to develop the computer program Compusyn and the Combination 
Index theorem, which is used to determine the Combination Index (CI) between drugs 
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(Figure 8). The combination-index theorem can establish the interaction between multiple 
drugs because the fraction of affected and unaffected—the EC50—of each drug is provided 
as a monotherapy after in vitro testing. Combination Indexes less than 1 (CI<1) are 
classified as synergistic; equal to 1 (CI=1) are additive; and greater than 1 (CI>1) are 
antagonistic. Table 2 shows the range of CI classifications. Before CI studies, the ED50 of 
each drug as a monotherapy has to be determined. 
 
Figure 8. The Combination Index Theorem. Figure 8 shows the derivations of the MEE that 
resulted in the development of the Combination Index Theorem. In these derivations, numbers 1 
and 2 are the theoretical representation of two different drugs used in combination, and x is the log 
[(D)1 + (D)2]. The other variables are as described for the MEE equation. 
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Range of Combination Index Description 
<0.1 Very strong synergism 
0.1–0.3 Strong synergism 
0.3–0.7 Synergism 
0.7–0.85 Moderate synergism 
0.85–0.9 Slight synergism 
0.9–1.10 Nearly additive 
1.10–1.20 Slight antagonism 
1.20–1.45 Moderate antagonism 
1.45–3.3 Antagonism 
3.3–10 Strong antagonism 
>10 Very strong antagonism 
Table 2. Range of Combination Indexes and their respective interpretations. 
Compusyn not only displays the CI between drugs, but also provides combinations of drug 
pairs by isobologram, the Dose-reduction Index (DRI) table and plot, the Median-
Effect plot, the Combination-Index plot, and the polygonogram (205). 
9.2.1. Isobologram 
As mentioned above, the isobologram analyzes the interaction between two drugs. Thus, 
when analyzing the CI of more than two drugs, the isobologram only partially represents 
the interaction among them. For example, if drugs A, B, and C are used in combination, 
the isobolograms of A and B; A and C; and B and C will give only an approximated 
representation of the interaction of all three drugs when they are used in combination. 
Compusyn, however, constructs the isobologram using Chou and Talalay’s Combination 
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Index theorem (Figure 9). Despite that, it will also give the interaction of only two drugs 
in combination.  
 
Figure 9. Isobologram generated by Compusyn. A) is a classical isobologram and B) is a 
normalized isobologram. Drugs 1 and 2 are theoretical examples of two drugs combined, and axis 
x and y represent the IC50 or the ED50 of each drug. Both ED50 and IC50 are interchangeable 
terms that represent a range of concentrations that result in 50% of the total effect. Figure extracted 
from reference (205). 
9.2.2. Dose-reduction Index (DRI) table and plot 
One main benefit of a synergistic drug combination is that it can enhance or maintain the 
effectivity of a therapy while reducing the doses of drugs used in combination. Given the 
effect of each drug as a monotherapy, Compusyn will generate a Dose Reduction Index 
(DRI) for all synergistic drug combinations. To calculate the DRI of drug combinations, it 
first is necessary to define the EC50 (the drug concentration that results in a half-maximum 
response) of each drug as a monotherapy. If the analysis is being done in vivo, the LD50 
(the dose of each monotherapy that kills 50% of the animals) needs to be stipulated. Based 
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on the MEE, the Combination Index theorem, and the EC50 of each drug, Compusyn 
generates the DRI table (Figure 10A), and the DRI plot (Figure 10B). The DRI measures 
how much of a dose of each drug can be reduced in combination to still produce a 
synergistic combination. The DRI also provides the predicted effect of each predicted 
synergistic combination. The DRI plot also compares the predicted synergistic 
combinations calculated by Compusyn, and the actual combinations tested in vitro or in 
vivo. 
 
Figure 10. DRI table and plot. DRI table (A), which was extracted from reference (210) as an 
example, represents the combination of the drugs Panobinostat and ZOL. The first column shows 
all the cell lines used in the experiment. The second column displays the CI, which are the 
Combination Indexes for each combination of Panobinostat and ZOL tested in each cell line. The 
number without parentheses represents the actual calculated CI for the actual drug combinations 
tested in the experiments, and the number inside parentheses is the CI suggested by Compusyn 
when the doses are reduced. The third column represents the DRI, which indicates how much the 
doses of Panobinostat and ZOL used in combination should be reduced to produce a more 
synergistic combination. The DRI plot (B), which was extracted from Chou–Talalay manuscript in 
reference (205), gives the visual representation of the tested drug doses (points and triangles) and 
the dose of drugs that should be used in combination as indicated by Compusyn (line). The plot 
also displays the fraction of affected (Fa) for each combination plotted. D1 and D2 are two different 
drugs that are used in combination, which, in this plot, shows that the DRI of drug 1 (D1) in 
combination is higher than the DRI of drug 2 (D2). 
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9.2.3. Median-Effect plot 
The Median-Effect plot shows the dose-effect relationship of each drug used in 
combination. Compusyn generates a dose-effect curve (Figure 10A) and the Median-
Effect plot, which is the same dose response curve log transformed (Figure 10B). The log-
transformed data clearly depicts the dose-effect relationship even when very low doses are 
used. This representation holds true for all dose-effect curves that follow the 
physicochemical principle of the mass-action law regardless of unit or mechanism of action 
(211). Since the Median-Effect plot yields a straight line, the theoretical minimum doses 
of two drugs combined allow the drawing of the full dose-effect curve, even when only a 
few doses were actually tested in vitro. That is why Compusyn can predict the dose-effect 
nature of these drugs combined and decide if a combination of drugs used in predicted 
doses will result in an effect that is greater, equal, or less than any dose of the individual 
drugs. 
 
Figure 11. Compusyn representation of the drug dose-effect curve. The drug-effect curve (A) 
is predicted and represented as a sigmoid curve. In the Median-Effect plot (B), there is a log-
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transformed representation of this curve, which clear visualizes the effect of very low doses of the 
drug. In this plot, the log [(fraction of affected fa)/ (fraction of unaffected fu)] yields a straight line 
with slope (m) and the x-intercept of log (Dm), where Dm equals the anti-log of the x-intercept. 
Figure 11 is extracted from reference (205). EC50 dose of drug with causes 50% of maximum 
effect; TD50 is the median toxic dose of a drug or toxin and is the dose at which toxicity occurs in 
50% of cases; LD50 is the dose that kills 50% of animals. 
9.2.4. Combination-Index plot 
The Combination-Index plot (Fa-CI) generated using Compusyn displays the interaction 
(synergism, additivity, or antagonism) of drugs used in combination with their respective 
predicted effects (Figure 11A). In theory, since both the isobologram and the Fa-CI plot 
generated in Compusyn are based on the Chou–Talalay Combination Index theorem, they 
should yield identical conclusions about the CI of drugs used in combination. The main 
difference between the isobologram and the Fa-CI plot is that the isobologram is dose-
oriented, whereas the Fa-CI plot is effect-oriented. In addition, while the isobologram 
shows the CI only between two drugs, the Fa-CI plot can simultaneously show the effects 
(Fa = fraction of affected) of multiple drugs in any number of combinations in the same 
graphical representation. The Fa-CI plot considers CI < 1 as synergistic; CI=1 additive; and 
CI> 1 antagonistic. The log-transformed Fa-CI (the Fa-log(CI)) is also provided by 
Compusyn, and it is useful to show very low synergism or very strong antagonism values 
(Figure 11B). The Fa-log(CI) plot not only reduces the out-of-scale points in the Fa-CI 
plot, but it also makes the presentation symmetrical with the additive effect localizing at 0 
since log (CI=1) is 0. Consequently, synergism is shown as a negative value and 
antagonism is shown as a positive value. 
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Figure 12. Combination-Index plot. The Fa-CI plot (A) displays the Combination Index of the 
drugs (y-axis) as a function of their effect, or the fraction of affected (Fa). In this graph, CI<0 
indicates synergism; CI = 1 additive effect; and CI > 1 antagonism. In the Fa-log (CI) (B), the Fa-
CI is log-transformed making the additive effect Log CI=0; synergism Log CI<0; and antagonism 
Log CI > 0. The line generated in the Fa-log (CI) represents drug combinations. Graph A was 
extracted from reference (205). 
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9.2.5. Polygonogram 
The concept of the polygonogram does not come from mathematical derivations but from 
practical utility (205, 212). The polygonogram displays an easy to understand visual 
depiction of multiple drugs used in combination and their CI. 
 
Figure 13. Polygonogram graphical representation. Figures (A) and (B) display examples of 
multiple drugs used in combination and their respective CIs. Figure 13 was extracted from 
reference (205). 
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10. In vitro assays to assess combinations among drugs 
10.1. Cell viability assays 
An in vitro quantitative cell viability assay is commonly used to test cells’ viability after 
being treated with drugs as monotherapies (e.g., EC50) or in combinations. The assay 
output produces a colorimetric indication that is proportional to the number of cells that 
survived treatment. There are several commercially available viability assay kits (e.g., Cell 
Counting Kit-8 (CCK-8), MTS assay, MTT assay, and others), and most of the kits are 
based on enzymatic conversion of tetrazolium chloride to formazan by cellular 
dehydrogenases and reductases to develop the colorimetric indication. Color intensity 
translates to optical-density values (OD values) through a 96-well plate reader that is set to 
register the OD values at absorbance level of 490nm. The enzymatic conversion of 
tetrazolium chloride to formazan is mostly done by enzymes that are active in viable cells 
with intact membranes and normal physiology. Because enzymes from cells that are going 
through apoptosis can also contribute to the production of formazan, the assay usually 
shows a level of background that does not reflect the number of cells that survive the 
treatment. To mitigate this limitation, 96-well plates treated with drugs are assessed at 
different time points so that the progression of the cells over time can be accurately 
determined.  
Viability assays, however, are not the best way to assess the efficiency of combination 
therapies involving radiation because when the cells are irradiated the DNA damage 
induces cell-cycle arrest, and cells become apoptotic a few days later. But even though 
irradiated cells can no longer proliferate and will not be viable after a few days, the cells 
can still efficiently convert tetrazolium chloride to formazan as cellular dehydrogenases 
are still active. Consequently, because irradiated cells can still form formazan they can give 
the erroneous impression that they are still viable and this is a limitation when viability 
assays are used to assess the cytotoxicity of combination therapies involving radiation. In 
this case different time points might not be sufficient to access viability of cells in later 
time points, as cells undergo apoptosis usually after five days of being irradiated. Most 
cells in culture start to die from nutrient starvation by this point, as media is not periodically 
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changed. Thus, when effects of radiation can be observed, cells are not dying due to 
irradiation but by high media acidity and nutrient starvation. In addition, later time points 
which would give a real representation of radiation effect cannot be accessed as viability 
assays have to be terminated usually by the 7th day from the start of treatment.  
10.2. Colony formation assay 
The colony formation assay (CFA) is an in vitro assay designed to assess whether cells can 
still proliferate, or, in case of cancer cells, still undergo unlimited replication after being 
treated with a therapy. The assay is based on the ability of a single cell to grow into a colony 
after being exposed to a given drug or combination of drugs. Before or after treatment, 
cells are seeded at appropriate dilutions to form colonies in two to three weeks post-
treatment. After this amount of time passes, the colonies are fixed, stained, and counted. 
Colony numbers in untreated plates determines the plating efficiency (Figure 12A), which 
reflects whether that untreated cell line has the potential to form colonies. After 
determining the plating efficiency, the colonies that form after being exposed to a particular 
treatment are counted to determine their survival fraction (Figure 12B).  
Although CFA can be used to assess the potential of any drug to inhibit cell proliferation, 
CFA is the gold standard in vitro method to determine the killing effect of radiation (213, 
214). The effect of radiation on cells is not immediate. After being irradiated, cells go 
through cell-cycle arrest and progress to apoptosis at least five days after the radiation-
induced DNA damage. Because CFA’s incubation time is two to three weeks, the assays 
properly reflect the efficacy of radiation during treatment. 
Figure 14. Colony formation assay equations to assess the potential of untreated cells to grow 
colonies (A) and to assess a therapy’s effectiveness in inhibiting colony growth (B). 
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11. Chapter I: Studying IFN-expressing oncolytic adenovirus in 
immunocompetent hamsters as a tool to improve IFN-therapy 
11.1. Introduction 
Pancreatic ductal adenocarcinoma (PDAC) may soon be the third-leading cause of cancer-
related death in the United States (215). Surgery is the most effective treatment for PDAC, 
but since most patients are diagnosed in the advanced stage of the disease, the majority of 
them are not candidates for surgical resection. Existing chemotherapies cannot cure PDAC, 
while new chemotherapy-based regimens such as FOLFIRINOX (129) and NAB-
paclitaxel plus Gemcitabine (216) have not meaningfully affected patients’ long-term 
survival rates. The lack of effective therapies against PDAC results in a five-year overall 
survival rate of 6%, which means that pancreatic cancer will become the second-leading 
cause of cancer-related death by 2017 (95). Although effective therapies are rare, clinical 
trials that treat PDAC patients with adjuvant IFN-α (IFN) therapy combined with radiation, 
5-FU, and Cisplatin (CDDP) have reported a 20–45% increase patients’ two-year survival 
rate (134-136), and a 35% increase patients’ five-year survival rate (134, 137, 138). Other 
trials, including a trial that added the drug Gemcitabine to the IFN-treatment protocol—
have reported a 30% increase in patients’ two-year survival rate (136). These trials were 
designed to combine the effectiveness of surgery with IFN’s chemo-radio sensitization and 
immunostimulatory effects (135, 137, 142-144). Although IFN-based therapeutic 
approaches have shown promising results, the effectiveness of IFN-therapy was limited by 
high IFN systemic toxicity, which causes strong flu-like symptoms and high patient drop 
out from therapy, and perceived low IFN concentrations intratumorally as the result of the 
rapid degradation of the cytokine in the bloodstream (139-141). These limitations 
hampered the full potential of IFN-therapy. 
The study of oncolytic viruses is a growing area in cancer research because they can be 
genetically modified to selectively replicate in and kill cancer cells. Examples of these 
types of viruses include T-VEC (Imlygic™) (217), an FDA-approved therapy against 
melanoma, and an adenovirus-based H101 therapy, approved in China to treat head and 
neck cancer (218). Our group has previously reported the use of an oncolytic adenovirus 
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(OAd) expressing human IFN-α (OAd-IFN) as a promising platform for selective and long-
term expression of IFN (25, 56). In this vector structure, we cloned the IFN gene into the 
adenoviral E3 region, which resulted in high expression of the cytokine in a replication-
dependent manner. We have demonstrated that OAd-IFN reduces tumor burden in human 
PDAC xenografts in mice. We also have showed that an OAd-expressing syngeneic 
hamster IFN (OAd-hamIFN) was highly effective in reducing the size of tumors and 
extending survival in both localized and disseminated PDAC in an immunocompetent 
syngeneic hamster model (25, 56, 87, 94). 
Here, in an attempt to improve the effectiveness of and overcome the limitations to this 
promising IFN-therapy, we tested the use of OAd-hamIFN in combination with 5-FU, 
Gemcitabine (GEM), Cisplatin (CDDP), and radiation in treatment schemes that resemble 
the IFN clinical trials mentioned above. We hypothesized that the replication-dependent 
expression of IFN by OAd-hamIFN will concentrate high levels of IFN in PDAC tumors 
and potentiate the cytokine chemo-radio sensitization capacity, while reducing its systemic 
toxicity. To assess the potential of OAd-hamIFN combinations with chemotherapy, 
radiation, and chemoradiation, we used hamster pancreatic cancer cells in vitro, as well as 
our previously published immunocompetent syngeneic Syrian Hamster model of PDAC as 
our pre-clinical model (94). In contrast to mice, Syrian hamsters support human-adenovirus 
replication(87). Thus, using a syngeneic hamster model as our in vivo platform is the most 
appropriate approach to better understand the effect of an IFN-expressing OAd in 
combination with chemoradiation to treat PDAC (87, 94). 
11.2. Materials and methods 
Cell lines 
The HP1, HAPT-1, PGHAM hamster pancreatic cancer cell lines were provided by Dr. 
Hollingsworth, University of Nebraska, NE, and Dr. Uchida, Nippon Medical School, 
Tokyo, Japan, respectively. Cells were cultured as previously described (94). 
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Adenovirus vectors 
Oncolytic adenovirus expressing hamster IFN alpha (OAd-hamIFN) was generated 
(Figure 1) as previously reported (94, 219). We incorporated the interferon gene into the 
adenoviral E3 region because of the well documented high level of transgene expression 
from this location. The Adenovirus Death Protein (ADP) was maintained in the adenoviral 
E3 region while all other nonessential E3 genes such as 12.5 K, 6.7K, gp19K, RID-α and 
RID-β, and 14.7K were deleted to accommodate the IFN gene. Overexpression of ADP—
an enhancer of apoptosis and cell killing—improves the ability of adenovirus to spread in 
pancreatic cancer cells and potentiates viral oncolytic capacity (25, 54, 56). The vector has 
incorporated the RGD-4C (Arginive-Glycine-Aspartic) motif in the HI loop of the 
adenovirus fiber and shifts viral tropism from the CAR receptor to integrins αvβ3 and αvβ5. 
As a non-IFN control, a counterpart vector expressing the firefly luciferase from the Ad E3 
region instead of IFN was used (OAd-LUC). All viruses were propagated in the 911 cell 
line, purified by double cesium chloride density gradient ultracentrifugation, and dialyzed 
against phosphate-buffered saline (PBS) with 10% glycerol. Vector biological titers were 
determined using the plaque-forming unit assay (PFU), and the number of viral particles 
(VP) were measured using spectrophotometer OD260. The VP/PFU ratio ranged from 10–
20. We confirmed the viral structure through PCR using primers specific for the fiber, ADP, 
IFN, and the transgenes (24, 25, 56, 220). 
 
Figure 1. Structure of the oncolytic adenovirus expressing hamster IFN alpha (OAd-hamIFN) 
and the control vector expressing luciferase. OAd-hamIFN is a replication-competent oncolytic 
adenovirus that expressesing the hamster IFN-alpha gene from the adenoviral E3 region. The 
control vector (OAd-LUC) has the same structure as OAd-hamIFN, but has a luciferase transgene 
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Chemotherapy drugs 
For the in vitro studies, we purchased Fluorouracil (5-FU), Gemcitabine (GEM), and 
Cisplatin (CDDP) from the University of Minnesota Boynton Pharmacy. The drugs were 
diluted and stored as described elsewhere (94). For in vivo experiments, we used diluted 
medical grade 5-FU in the concentration of 50mg/ml, which was also purchased from 
University of Minnesota Boynton Pharmacy. 
Colony formation assay 
We platted 1.0 x 106 cells in 75cm2 cell-culture flasks and incubated them at 37⁰C in a 5% 
CO2 humidified incubator. After 24 hours, we infected the cells with OAd-hamIFN or OAd-
LUC. One day after infection, we irradiated the flasks representing virus + radiation and 
virus + 5-FU + radiation groups using the X-RAD 320 X-ray system. The X-ray platform 
was positioned 50cm from the bottom of the machine and we used Filter 1 (2.0mm 
Aluminum/ Half Value Layer 1.0mm Cu). We then placed the radiation flasks in humidified 
incubator 37⁰C/5% CO2 for 30 minutes. After the incubation, we trypsinized the cells with 
0.25% Trypsin EDTA 1X (Corning, NY) and counted them using an automated cell counter 
(Cellometer Auto T4, Nexcellon Biosciences, Lawrence, MA). We then serially diluted the 
cells using DMEM media (10% FBS and 1% Penicillin/Streptomycin) and plated them in 
10cm cell-culture dishes that contained only media (OAd-hamIFN + Radiation group) or 
media with 5-FU (OAd-hamIFN + 5-FU + Radiation group). The cell groups representing 
virus + 5-FU were trypsinized, counted, serially diluted, and platted in 10cm culture dishes 
containing media with chemotherapy. Cells in the untreated and OAd-hamIFN treated 
groups were trypsinized, counted, serially diluted, and platted in 10cm culture dishes with 
cell-culture media. All the plates were maintained in the humidifier incubator at 37.8°C/5% 
CO2, and we replaced the cell-culture media in each plate every two days. When all the 
plated cells in the untreated group started to show colonies, all the plates in the experiment 
were fixed with 4% Formalin for one hour at room temperature. We then stained the plates 
overnight with 1% Methylene blue, washed them with 1X PBS, and allowed them to air 
dry. We then counted the colonies and used the following formulas to estimate assay results: 
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Plating efficiency =
𝑁𝑢𝑚𝑏𝑒𝑟	𝑜𝑓	𝑐𝑜𝑙𝑜𝑛𝑖𝑒𝑠	𝑖𝑛	𝑢𝑛𝑡𝑟𝑒𝑎𝑡𝑒𝑑	𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑛𝑢𝑚𝑏𝑒𝑟	𝑜𝑓	𝑝𝑙𝑎𝑡𝑒𝑑	𝑐𝑒𝑙𝑙𝑠	𝑖𝑛	𝑢𝑛𝑡𝑟𝑒𝑎𝑡𝑒𝑑	𝑐𝑜𝑛𝑡𝑟𝑜𝑙 
 
Cell survival frac7on =
Number of colonies
Number of plated cells × Pla7ng eﬃciency 
Cell Viability Assay 
To perform our quantitative analyses, we plated 8x103 cells/well in 96-well plates and 
infected them with 100 viral particles (VP)/cell of OAd-hamIFN or OAd-LUC. Four hours 
later, we replaced the infectious media with Dulbecco’s Modified Eagle Medium (DMEM) 
with 5% Fetal Bovine Serum (FBS), 1% Penicillin/Streptomycin containing 5-FU; GEM, 
or CDDP, and further incubated the plates. We then performed a viability assay with the 
CellTiter-96®Aqueous One-Solution Cell Proliferation Assay MTS reagent (Promega) 
according to the manufacturer’s instructions. For the Crystal Violet Assay, we plated 2x105 
cells/well in 12-well plates and infected them with 50 or 100 VP/cell. Cells were fixed and 
stained as previously described (94). 
Combination Index analysis 
Using Compusyn, we calculated the Combination Index (CI) to determine the synergism 
(CI<1), antagonism (CI>1), or additive effect (CI=1) between the virus, chemotherapy, and 
radiation (205). The EC50 of each treatment alone (OAd-hamIFN, 5-FU, and radiation) 
was quantitatively determined by the Colony Formation Assay (CFA) in HP1 and PGHAM 
cells, and the EC50 values were entered into Compusyn as monotherapies. We quantified 
the cytotoxicity of combination treatments using the CFA in same cell lines, and entered 
into Compusyn the killing effect of the combination therapies. We generated the final CI 
report using a non-constant ratio between the therapies. We considered strong synergism 
to exist when the CI<0.5 and moderate synergism when the CI=0.6–0.9. 
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In vivo experiment 
Combinations of OAd-hamIFN with 5-FU, radiation, and 5-FU + radiation 
We subcutaneously injected HP1 cells (2 x 106) suspended in 100 µl of PBS into both hind 
legs of female Golden Syrian Hamsters obtained from the Harlan Sprague Dawley 
facilities. The animals were divided in eight groups comprised of four animals with two 
tumors each. When a tumor’s diameter reached 8–10 mm, we injected it with 2 x 1011 VP 
diluted in 50 µl PBS. The day of this injection was considered day 0. 
On days 1, 3, 6, and 10, we gave each animal intraperitoneal injections of 20 mg/kg 5-FU 
and on day 3 we irradiated them with 8 Gy of radiation. The animals were then anesthetized 
with a mixture of 100 mg/kg Ketamine and 15 mg/kg Xylazine and placed in a customized 
radiation chamber where the tumors were exposed to radiation while their bodies were 
protected by a lead shield. We measured tumor diameter twice a week using calipers and 
calculated tumor volume using the formula (width2 × length)/2. The animals were 
euthanized according to IACUC guidelines. 
Assessment of OAd-hamIFN replication in HP1 tumors 
We subcutaneously injected HP1 cells (2 x 106) suspended in 100 µl of PBS into both hind 
legs of female Golden Syrian Hamsters obtained from the Harlan Sprague Dawley 
facilities. The animals were divided into three groups comprised of five animals with 2 
tumors each. When a tumor’s diameter reached 8–10mm, we injected it with 50µL of PBS 
in virus in the concentration of 2 x 1012 VP/cell. Seven days after the initial infection, we 
harvested the tumors and froze them at -80°C. The frozen tumors were fixed with buffered 
formaldehyde and embedded in OCT cryoprotectant (15% sucrose, 0.1 mol/L phosphate 
buffer, pH 7.2). We then froze the tumors in liquid nitrogen, cut them into 15-µM slices, 
and placed them in silane-covered slides. These slices were then incubated at room 
temperature with the primary goat anti-hexon polyclonal antibody, washed three times, and 
incubated again with FITC-labeled donkey anti-goat secondary antibody. After this 
incubation period, we performed counterstaining with Hoechst 33342. Hexon staining was 
visualized using confocal microscope. Staining analysis was qualitative.  
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Radiation 
We administered radiation in vitro and in vivo using the X-RAD 320 X-ray system (North 
Btanford, CT). The X-ray radiation platform was positioned 50cm from bottom of the 
machine and we used Filter 1 (2.0 mm Aluminum/ Half Value Layer 1.0mm Cu). 
Statistical analysis 
In vivo, we analyzed tumor volume over time using a linear mixed model. The outcome 
(tumor volume) was the square-root transformed to improve the model fit. The fixed effects 
included the treatment group; time (continuous); and the interaction between group and 
time. Random intercept and time effects were included for each animal. Twelve pairwise 
group tests (model contrasts) analyzed whether the slope (change over time) differed 
between treatment groups. We obtained p-values relative to the 5-FU + Radiation group 
because this was the historical control group compared to IFN-based therapies in clinical 
trials. For the survival study, we compared the 5-FU + Radiation and all other treatment 
groups using standard log-rank tests. The stepdown Bonferroni method adjusted for 
multiple tests in the in vivo and survival studies. For the in vitro cell viability study, we 
performed two-way ANOVA for each cell line and treatment condition, with a three-level 
treatment dose effect and a binary virus effect. 
11.3. Results 
Potentiation of chemotherapy by OAd-hamIFN 
We assessed the cytotoxicity of OAd-hamIFN (Figure 1) in combination with 5-FU, GEM, 
and CDDP chemotherapy drugs in vitro. The qualitative analyses using crystal violet 
(Figure 2) and quantitative analyses using cell viability assays (Figure 3) showed that 
compared to virus or chemotherapy alone, OAd-hamIFN enhanced the cytotoxicity of all 
the drugs in both cell lines. We observed that the combination of OAd-hamIFN and 5-FU 
resulted in the strongest potentiation of cell cytotoxicity. While the cytotoxicity of 
treatments where OAdhamIFN was combined with CDDP or GEM varied across different 
cell lines, the combination of the virus and 5-FU resulted in similar cytotoxic profiles in 
all cell lines. Although CDDP monotherapy was not effective in killing HP1 and HAPT-1 
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cells, using CDDP in combination with OAd-hamIFN resulted in the greatest enhancement 
of cytotoxicity, which highlights the virus’ role in breaking cell resistance to chemotherapy. 
This data indicates that an IFN-expressing OAd can significantly enhance the killing effect 
of chemotherapeutics used in IFN clinical trials. 
 
Figure 2. Qualitative analysis of the cytocidal effect of OAd-hamIFN combined with 
chemotherapies. Combinations of OAd-hamIFN with 5-FU, Cisplatin (CDDP), and Gemcitabine 
(GEM) were analyzed for their cytocidal effect in HP1 and PGHAM hamster pancreatic cancer cell 
lines using the crystal violet assay. In both cell lines, a combination of the virus and chemotherapy 
showed superior cell-killing effect compared to the virus’s cytotoxicity or chemotherapy alone. By 
increasing of the doses of the virus and chemotherapy, the killing effect was further improved. VP: 
viral particle. 15 
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Figure 3. Quantitative analysis of the cytocidal effect of OAd-hamIFN combined with 
chemotherapy. We compared the cytotoxicity of 100 VP/cell of OAd-hamIFN and chemo-
monotherapies to the cytocidal effect of OAd-hamIFN combination therapies with respective doses 
of 5-FU, GEM, and CDDP. Within each of the nine conditions, we performed a two-way ANOVA 
with dose and virus effects. All the effects had p < 0.025, which indicates that the killing effect of 
OAd-hamIFN + Chemotherapy was superior to the killing effect of chemotherapy or OAd-hamIFN 
alone. The standard deviation was used to represent the variation within individual treatments (bars 
on the top of histogram). 16 
Contribution of IFN to chemotherapy cytotoxicity 
We used cell viability assays to test whether IFN expressed by OAd-hamIFN could enhance 
cytotoxicity in combinations of OAd-hamIFN with 5-FU, GEM, and CDDP (Figure 4). A 
comparison of OAd-hamIFN and non-IFN-expressing counterpart vector (OAd-LUC) 
combined with 5-FU, GEM, and CDDP showed that IFN expressed by OAd-hamIFN 
enhanced the killing effect of not only OAd, but also potentiated the cytotoxicity in HP1 
cells of all chemotherapy drugs. The expression of IFN seemed essential to boosting the 
cytotoxic effect of chemotherapy. Of note, IFN exhibited a greater contribution toward 
accentuating cell killing with GEM and CDDP than with 5-FU. 
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Figure 4. Contribution of IFN expressed by the adenovirus to increase the cytotoxicity of 
viro-chemotherapies. We used the cell viability assay to evaluate contribution of IFN expression 
to enhance cytoxicity of viro-chemotherapies in HP1 cells. We compared OAd-hamIFN combined 
with 5-FU, GEM, and CDDP to the control vector (OAd-LUC) each at the concentration of 100 
VP/cell paired with the same concentrations of chemotherapeutics. Within each of the three 
treatment conditions, we performed a two-way ANOVA with dose and virus effects. Within each 
condition, the virus effect (OAd-LUC vs OAd-ham IFN) had a p < 0.01. The standard deviation was 
used to represent the variation within individual treatments (bars on the top of histogram). 17 
Potentiation of radiation and chemoradiation by OAd-hamIFN 
To further analyze the effect of radiation on the effectiveness of OAd-hamIFN treatments, 
we used the crystal violet assay to test combinations of OAd-hamIFN with 5-FU, radiation, 
and 5-FU+radiation in HP1 cells. (Figure 5). We used 5-FU as the drug of choice because 
combinations of the virus with 5-FU showed similar cytotoxicity profiles in all the cells 
(Figures 2 and 3). 5-FU also was given to patients during all the chemotherapy cycles in 
IFN clinical trials. Our qualitative assessment reinforced the fact that OAd-hamIFN 
enhanced the killing effect of 5-FU (Figure 5A), and also showed that the virus enhanced 
the cytotoxicity of radiation (Figure 5B-2). Treatments of OAd-hamIFN in combination 
with 5-FU+radiation—which mimicked the use of IFN + 5-FU + Radiation in IFN-clinical 
trials—was the most cytotoxic viral combination we tested (Figure 5B-4). Importantly, the 
treatments of OAd-hamIFN combined with higher doses of 5-FU (Figure 5B-2), radiation 
(Figure 5B-2), or 5-FU + radiation (Figure 5B-4) were more effective in killing cancer 
cells than treatments with 5-FU + Radiation (Figure 5-3). The 5-FU + radiation regimen 
was the standard control that the clinical trials used to determine the efficacy of IFN-based 
therapies (134, 137, 144, 149). Overall, including IFN-expressing OAd potentiated the 
killing effect of all the different components used in IFN-based therapies in clinical trials, 
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which reinforces the view that the virus has the potential to potentiate the effectiveness of 
cancer therapy. 
 
Figure 5. Addition of radiation to viro-chemotherapy resulted in superior killing effect. We 
analyzed the cytotoxicity of OAd-hamIFN combined with 5-FU and radiation using the crystal violet 
assay. We compared the cytocidal effect of combination therapy with OAd-hamIFN (50 or 100 
VP/cell) and 5-FU (5, 10, and 20 µM) to cytocidal effect of combinations of OAd-hamIFN and 5-FU 
in the same concentrations, but with added radiation (4Gy). 18 
OAd-hamIFN combinations with chemotherapy, radiation, and chemoradiation are 
highly synergistic 
To characterize the interaction between the therapeutic agents combined with OAd-
hamIFN, we performed the synergy analysis as described by Chou and Talalay (205). We 
used the colony-formation method because it is the gold-standard assay for investigating 
the radio-sensitivity of cancer cells (Figure 6). The assay output showed that treatments of 
OAd-hamIFN combined with 5-FU, radiation, and 5-FU+radiation were efficient and 
inhibited the formation of more than 50% of colonies after treatment. Because PGHAM 
cells were more resistant to OAd-hamIFN, 5-FU, and radiation as monotherapies, only 
combination treatments with higher doses of the virus, 5-FU, or radiation combined 
strongly inhibited colony formation. In contrast, the treatments that mimicked IFN-therapy 
in humans (OAd-hamIFN + 5-FU + Radiation) remarkably inhibited colony formation 
regardless of the doses of the chemotherapeutics. In both cell lines, an analysis of the 
Combination Index showed that all the treatments that included OAd-hamIFN were 
synergistic (CI<1), and that strong synergism (C < 0.5) occurred when OAd-hamIFN was 
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combined with 5-FU + radiation. Although synergism and strong cytotoxicity in HP1 cells 
was observed in all the OAd-hamIFN treatments, in the PGHAM cells the same happened 
only when the treatments included higher doses of therapeutics or when the triple therapy 
(OAd-hamIFN + 5-FU + Radiation) was used. Therefore, the remarkable synergy between 
IFN-expressing OAd and conventional PDAC therapeutics provides a great opportunity to 
improve the IFN-therapy’s anti-tumor effects while making the therapy less toxic. 
 
Figure 6. Quantification of cytotoxicity and synergy of OAd-hamIFN combination therapies 
based on the colony formation assay. Combination of OAd-hamIFN with 5-FU, radiation, and 
chemoradiation reduced the number of colonies formed in hamster pancreatic cancer cell lines. We 
identified strong synergism (CI < 1) in the groups treated with OAd-hamIFN in combination with 
chemotherapy, radiation, and chemoradiation. In both cell lines, combinations of OAd-hamIFN and 
chemoradiation in higher doses resulted in the strongest killing effect and synergistic interaction. 
The Chou–Talalay method was used to determine the Combination Index (CI). Synergistic effect 
(CI < 1); additive effect (CI = 10); antagonistic effect (CI > 1). 19 
Inhibition of tumor growth by OAd-hamIFN combination therapies in Syrian 
hamsters 
We also tested the effectiveness of OAd-hamIFN treatments in the syngeneic 
immunocompetent hamster model of pancreatic cancer (Figure 7A). The treatments that 
included OAd-hamIFN resulted in stronger tumor growth inhibition than the treatments 
without the virus (Figure 7B). The strongest anti-tumor effect was observed in animals 
treated with the combination of OAd-hamIFN + 5-FU + radiation or the combination of 
OAd hamIFN + radiation. Compared to animals only treated with 5-FU + radiation (a 
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control group used in prior IFN clinical trials), which control group averaged a 358% 
increase in the anti-tumor effect between Day 0 and Day 25, the anti-tumor effect in the 
triple-therapy group increased an additional 11% (p=0.0021 vs controls) and the anti-tumor 
effect of OAD hamIFN + radiation group increased an additional 44% (p=0.01). One 
animal that was treated with the triple therapy experienced complete tumor elimination.  
Although the animals that were treated with OAd-hamIFN + 5-FU had smaller tumors than 
the animals in the control group (5-FU + radiation), the anti-tumor effect was not 
statistically significant (180% average increase at day 25; p=0.41). Comparisons between 
animals treated with OAd-LUC + Radiation and OAd-hamIFN + Radiation showed that 
IFN expressed by OAd-hamIFN greatly contributed to stronger tumor growth inhibition. 
Finally, in addition to the strongest anti-tumor effect, the animals treated with viral 
therapies experienced the slowest regrowth of the tumors. 
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Figure 7. Improved anti-tumor effect and survival of OAd-hamIFN combination therapies in 
vivo. We compared the anti-tumor effect and survival of combination therapy groups against the 
chemoradiation group (5-FU + Radiation). (A) Treatment schedule used in hamsters. (B) Besides 
showing the strongest anti-tumor effect, the animals treated with viral therapies demonstrated the 
slowest tumor regrowth. (C) The survival rate of animals treated with OAd-hamIFN combined with 
5FU and radiation was significantly improved. The animals in the untreated and chemoradiation 
groups were euthanized earlier because of tumor size and ascites. p < 0.05 vs Radiation+5-FU 
(*); p < 0.005 (**) vs Radiation+5-FU; p<0.01 vs OAd-Luc+radiation (#).20 
Survival study in Syrian hamsters 
We monitored the survival of hamsters treated with OAd-hamIFN combined with 5-FU, 
radiation and 5-FU + radiation for 45 days after their initial treatment (Figure 7C). 
treatments with 5-FU or radiation as monotherapies were not effective—the survival rates 
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were similar to those of untreated animals (median 21 days). The animals that were treated 
with OAd-hamIFN combination treatments, however, survived longer than the 
monotherapy groups and the control-therapy group (5-FU + Radiation; median survival of 
25 days), which represent conventional PDAC treatments. The hamster in the group that 
received OAd-hamIFN + Radiation and the triple-therapy (OAdhamIFN + 5-FU + 
Radiation) survived the longest of all the groups—a median survival period of 45 days 
(p=0.06 and 0.02 vs controls, respectively). The triple therapy was the only therapy that 
showed a statistically significant survival period compared to the control chemoradiation 
group and was the only therapy that resulted in complete tumor regression in one animal. 
The OAd-hamIFN + 5-FU treatment group also had a longer survival period (median 32 
days) compared to the 5-FU + Radiation control group, but this result was not statistically 
significant. A comparison of the survival rate in the OAd-LUC + Radiation group and the 
group treated with OAd-hamIFN + Radiation showed that the virus’s expression of IFN 
significantly contributed to improved survival when virotherapy is combined with 
radiotherapy. Our survival data correlated well with the previous therapeutic study (Figure 
7B), and supports our hypothesis that using IFN-expressing OAd in treatment regimens 
that mimic IFN-based therapy may extend human patients’ survival periods. 
Replication of OAd-hamIFN in immunocompetent hamsters 
Because hamsters are immunocompetent, it is possible that infecting a tumor with OAd-
hamIFN can stimulate an anti-viral immune response that can stop OAd-hamIFN 
replication in the tumor (Figure 8). To assess the replication of OAd-hamIFN in hamsters 
bearing HP1 tumors, we compared replication of non-IFN expressing OAd (OAd-LUC) 
with replication of OAd-hamIFN in tumors seven days post-infection of tumors. To do that 
comparison, we stained for the adenovirus hexon protein, which is a component of 
adenovirus capsid. Hexon is coded by the adenovirus’s late genes, and presence of this 
protein indicates that the virus can complete a full replication cycle in infected cells. The 
data showed that both viruses could replicate in HP1 tumors, and that although OAd-
hamIFN expresses a immunostimulatory cytokine, the replication of this vector was not 
inhibited. Therefore, using IFN-expressing OAd in immunocompetent hamsters is not only 
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capable of potentiating the effect of chemoradiation, but also holds the potential to 
stimulate anti-tumor immunity by releasing tumor-specific peptides during oncolysis. 
 
Figure 8. Replication of OAd-hamIFN in immunocompetent hamsters. We compared the 
replication of a non-IFN expressing OAd (OAd-LUC) and an IFN-expressing OAd (OAd-hamIFN) 
in HP1 tumors in immunocompetent hamsters. We stained the Hexon protein—a capsid protein 
coded by the adenovirus’s late genes—with FITC seven days after viral infection. The data showed 
that both viruses could replicate in tumors and that the fact OAd-hamIFN expresses an 
immunostimulatory cytokine did not abolished viral replication.  
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11.4. Figures 
 
Figure 1. Structure of the oncolytic adenovirus expressing hamster IFN alpha (OAd-hamIFN) 
and the control vector expressing luciferase. OAd-hamIFN is a replication-competent oncolytic 
adenovirus that expressesing the hamster IFN-alpha gene from the adenoviral E3 region. The 
control vector (OAd-LUC) has the same structure as OAd-hamIFN, but has a luciferase transgene 
instead of hamIFN. 21 
 
Figure 2. Qualitative analysis of the cytocidal effect of OAd-hamIFN combined with 
chemotherapies. Combinations of OAd-hamIFN with 5-FU, Cisplatin (CDDP), and Gemcitabine 
(GEM) were analyzed for their cytocidal effect in HP1 and PGHAM hamster pancreatic cancer cell 
lines using the crystal violet assay. In both cell lines, a combination of the virus and chemotherapy 
showed superior cell-killing effect compared to the virus’s cytotoxicity or chemotherapy alone. By 
increasing of the doses of the virus and chemotherapy, the killing effect was further improved. VP: 
viral particle. 22 
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Figure 3. Quantitative analysis of the cytocidal effect of OAd-hamIFN combined with 
chemotherapy. We compared the cytotoxicity of 100 VP/cell of OAd-hamIFN and chemo-
monotherapies to the cytocidal effect of OAd-hamIFN combination therapies with respective doses 
of 5-FU, GEM, and CDDP. Within each of the nine conditions, we performed a two-way ANOVA 
with dose and virus effects. All the effects had p < 0.025, which indicates that the killing effect of 
OAd-hamIFN + Chemotherapy was superior to the killing effect of chemotherapy or OAd-hamIFN 
alone. The standard deviation was used to represent the variation within individual treatments (bars 
on the top of histogram). 23 
 
Figure 4. Contribution of IFN expressed by the adenovirus to increase the cytotoxicity of 
viro-chemotherapies. We used the cell viability assay to evaluate contribution of IFN expression 
to enhance cytoxicity of viro-chemotherapies in HP1 cells. We compared OAd-hamIFN combined 
with 5-FU, GEM, and CDDP to the control vector (OAd-LUC) paired with the same concentrations 
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of chemotherapeutics. Within each of the three treatment conditions, we performed a two-way 
ANOVA with dose and virus effects. Within each condition, the virus effect (OAd-LUC vs OAd-ham 
IFN) had a p < 0.01. The standard deviation was used to represent the variation within individual 
treatments (bars on the top of histogram). 24 
 
Figure 5. Addition of radiation to viro-chemotherapy resulted in superior killing effect. We 
analyzed the cytotoxicity of OAd-hamIFN combined with 5-FU and radiation using the crystal violet 
assay. We compared the cytocidal effect of combination therapy with OAd-hamIFN (50 or 100 
VP/cell) and 5-FU (5, 10, and 20 µM) to cytocidal effect of combinations of OAd-hamIFN and 5-FU 
in the same concentrations, but with added radiation (4Gy). 25 
 
Figure 6. Quantification of cytotoxicity and synergy of OAd-hamIFN combination therapies 
based on the colony formation assay. Combination of OAd-hamIFN with 5-FU, radiation, and 
chemoradiation reduced the number of colonies formed in hamster pancreatic cancer cell lines. We 
identified strong synergism (CI < 1) in the groups treated with OAd-hamIFN in combination with 
chemotherapy, radiation, and chemoradiation. In both cell lines, combinations of OAd-hamIFN and 
chemoradiation in higher doses resulted in the strongest killing effect and synergistic interaction. 
The Chou–Talalay method was used to determine the Combination Index (CI). Synergistic effect 
(CI < 1); additive effect (CI = 10); antagonistic effect (CI > 1). 26 
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Figure 7. Improved anti-tumor effect and survival of OAd-hamIFN combination therapies in 
vivo. We compared the anti-tumor effect and survival of combination therapy groups against the 
chemoradiation group (5-FU + Radiation). (A) Treatment schedule used in hamsters. (B) Besides 
showing the strongest anti-tumor effect, the animals treated with viral therapies demonstrated the 
slowest tumor regrowth. (C) The survival rate of animals treated with OAd-hamIFN combined with 
5FU and radiation was significantly improved. The animals in the untreated and chemoradiation 
groups were euthanized earlier because of tumor size and ascites. p < 0.05 vs Radiation+5-FU 
(*); p < 0.005 (**) vs Radiation+5-FU; p<0.01 vs OAd-Luc+radiation (#).27 
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Figure 8. Replication of OAd-hamIFN in immunocompetent hamsters. We compared the 
replication of a non-IFN expressing OAd (OAd-LUC) and an IFN-expressing OAd (OAd-hamIFN) 
in HP1 tumors in immunocompetent hamsters. We stained the Hexon protein—a capsid protein 
coded by the adenovirus’s late genes—with FITC seven days after viral infection. The data showed 
that both viruses could replicate in tumors and that the fact OAd-hamIFN expresses an 
immunostimulatory cytokine did not abolished viral replication. 28 
11.5. Discussion 
We investigated the use of a replication-competent oncolytic adenovirus expressing IFN as 
a tool to boost the efficacy and overcome the limitations of IFN-based chemoradiation 
therapy, which is one of few therapeutic protocols that has been effective in treating PDAC. 
We used a Syrian hamster model to conduct our studies because Syrian hamsters are 
permissive to human-adenovirus replication and they provide a unique immunocompetent 
model to objectively analyze the effect of an adenovirus-produced immunostimulatory 
cytokine. Using this model, we assessed the use of OAd-expressing hamster IFN in 
therapeutic protocols similar to the IFN-based therapy used in prior PDAC clinical trials. 
We believed that using OAd—which is known to enhance the killing effect of 
chemotherapy and radiation (25, 56, 94, 221-224)—combined with a chemo-radio 
sensitizer such as IFN would significantly improve the effectiveness of chemoradiation 
therapy. 
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Our data showed that IFN expressed by OAd-hamIFN augmented the capability of OAd to 
sensitize cells to 5-FU, GEM, and CDDP. The potentiation effect of these drugs is 
extremely important because they are commonly used to treat pancreatic cancer. We also 
demonstrated that using OAd-hamIFN in combination with 5-FU, radiation, or 5-FU + 
radiation enhanced the killing of cells in vitro, and resulted in the most effective treatments 
in vivo. Most importantly, the treatment of OAd-hamIFN in combination with 5-FU and 
radiation mimicked IFN therapy in clinical trials and was consistently highly effective in 
eliminating cancer cells in vitro and in vivo. These data support our conclusion that adding 
an IFN-expressing OAd to chemotherapy, radiation, or chemoradiation is a promising 
approach to further improving already one of the most promising pancreatic cancer 
therapies. 
The Combination Index (CI) analysis showed that double-therapy treatments of OAd-
hamIFN with 5-FU or radiation were synergistic (CI<1), and that triple-therapy treatments 
(OAd-hamIFN + 5-FU + Radiation) were strongly synergistic (CI<0.5). In HP1 cells, all 
the viral treatments that showed synergism correlated with strong cytotoxicity, which 
indicates that the synergism translated to treatment efficacy. In PGHAM cells, the 
synergism in double-therapies groups (OAd-hamIFN + 5-FU and OAd-hamIFN + 
Radiation) correlated with strong cytotoxicity but only when higher doses of therapeutics 
were used. This result can be explained by the fact that PGHAM cells were more resistant 
to killing by virus, 5-FU, and radiation as single therapies. Nevertheless, using OAd-
hamIFN in combination with both 5-FU and radiation resulted in highly synergistic and 
cytotoxic treatments regardless of the dose of therapeutics used. This result, therefore, 
suggests that the chemo-radio sensitization capacity of both the virus and IFN contributed 
to improve treatment efficacy even when cells are not susceptible to monotherapies. 
Based on prior reports of other groups, we expected this synergistic interaction between 
OAd-hamIFN and radiation, 5-FU, and chemoradiation. Radiation predominantly causes 
double-strand breaks (DSB) in cell DNA, which leads to mitosis crisis and cell apoptosis 
(146, 225). The adenovirus E4 proteins impede DSB repair by binding and inhibiting DNA-
dependent protein kinase (DNA-PK), which is one of the main components of the non-
homologous end joining (NHEJ) repair pathway (224, 226). Therefore, the strong 
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synergism between radiation and OAd-hamIFN is supposed to be a combination of 
inhibition of DNA repair by OAd and the radio-sensitization effect of IFN expressed by 
the virus. There are no clear reports exploring the mechanism of action by which OAd 
sensitizes cells to chemotherapy drugs. It is known that IFN induces the double stranded 
RNA-activated protein kinase (PKR) in cells, and that PKR shuts down protein translation 
(227) . It is possible that that inhibition of protein synthesis combined with the DNA 
damage caused by 5-FU leads to synergism in OAd-hamIFN combinations with 5-FU. In 
addition, by manipulating cells to produce new viral progenies instead of cellular proteins, 
OAd contributes to the potentiation of cell stress and cell death when IFN and 5-FU are 
present. All these concepts could play a role in creating the strong synergism observed 
when OAd-hamIFN is combined with both 5-FU and radiotherapy. 
Previous work from our group reported that OAd-hamIFN as a single therapy in the 
hamster model of pancreatic cancer resulted in an impressive therapeutic response (94). 
Current in vivo data using the same model showed that treatment with OAd-hamIFN in 
combination with 5-FU or radiation—and especially 5-FU + Radiation—resulted in 
superior inhibition of tumor growth, improved survival, and delayed tumor regrowth 
compared to the chemo-radiotherapy group, which is a conventional PDAC treatment. 
Animals that were treated with triple-combination therapy (OAd-hamIFN + 5-FU + 
Radiation) showed the strongest anti-tumor effect in our study. In fact, one animal 
displayed complete tumor remission. Although no animals showed tumor remission in the 
group we treated with OAd-hamIFN + Radiation, the anti-tumor effect and survival in this 
group was similar to the triple-combination group. These data highlight the concept that 
OAd-hamIFN not only improves the anti-tumor effect of chemoradiation, but also greatly 
potentiates the efficacy of radiotherapy alone. This suggests that the calculated synergism 
of OAd-hamIFN + Radiation treatments in vitro might be translatable to a therapeutic effect 
in vivo. Comparison between the group treated with OAd-LUC + Radiation and the group 
treated with OAd-hamIFN + Radiation also indicates that the presence of IFN is essential 
for enhancing the anti-tumor effect of radiotherapy. It is well known that radiation can 
potentiate the systemic efficacy of immunostimulatory cytokines like IFN by activating 
innate and adaptive immune responses during treatment (228, 229). As OAd releases 
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tumor-specific peptides during oncolysis and because IFN stimulates the maturation and 
activation of antigen-presenting cells, the activity of T-helper cells, and enhances MHC-I 
expression (137, 143), it is possible that the improved therapeutic response in animals 
treated with OAd-hamIFN and radiation is the result of the formation of an anti-tumor 
immune response. The remarkable therapeutic effect shown in animals treated with OAd-
hamIFN + Radiation suggests that chemotherapy could be excluded from the IFN therapy 
protocol for patients that who cannot tolerate its toxicity. 
Although the animals treated with OAd-hamIFN in combination with 5-FU with smaller 
tumors survived longer compared to the chemo-radiotherapy control group, this result was 
not statistically significant. The decreased efficacy of 5-FU regimens in vivo could be 
explained by the short-half-life of 5-FU (approximately 30 minutes), and the long intervals 
between each 5-FU administration to the animals. In human clinical trials, 5-FU is 
continuously administered to patients to maintain a constant concentration of the drug in 
the blood (135-137), but in our animal model we administered the drug every 2–4 days. 
While the constant administration of 5-FU to animals is not feasible, it is possible that a 
more frequent chemotherapy injection protocol could have improved the efficacy of OAd-
hamIFN combinations with 5-FU. Despite a weaker 5-FU regimen, using 5-FU in triple 
combinations (OAd-hamIFN + 5-FU + Radiation) resulted in the strongest therapeutic 
effect in the study. This observation suggests that the strong synergism (CI<0.5) found in 
combinations of virus and chemoradiation in vitro might have contributed to potentiate the 
anti-tumor effect of the  triple combination in vivo. 
Another important aspect of our study is that all groups that we treated with OAd-hamIFN 
therapies showed delayed tumor regrowth compared to the non-OAd-treated groups. 
Although our project did not assess it, the stimulation of an anti-tumor immune response 
in OAd-treated animals could be responsible for reduced tumor recurrence. A report by 
Aoki and colleagues supports this hypothesis. That report indicated that injecting a tumor 
with an IFN-expressing adenovirus reduced not only the size of the tumor, but also caused 
an NK-mediated anti-tumor effect in a contralateral untreated tumor (119). 
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Thus, because we used the immunocompetent hamster model of PDAC, we believe that 
the stimulation of NK cells could have contributed to delayed tumor regrowth in OAd-
hamIFN treated animals. As replication of IFN-expressing OAd was not inhibited in 
immunocompetent hamsters, we believe that oncolysis by the virus, which exposes tumor 
specific peptides to the immune system, combined with immunostimulatory effect of IFN 
contributed to anti-tumor immune response formation during therapy. Even though the 
tools for immunological analyses in hamsters are currently limited, a thorough evaluation 
of the stimulation of anti-tumor immunity in OAd-hamIFN-treated hamsters is necessary 
to better understand the formation of anti-tumor immunity. 
In summary, our data suggest that using IFN-expressing oncolytic adenovirus in treatment 
protocols involving chemotherapy, radiation, or chemoradiation can provide an effective 
therapy for PDAC. The synergism between IFN-expressing OAd and chemotherapy, 
radiation, and chemoradiation may allow physicians to reduce the therapeutic doses used 
in IFN-based regimens, which will contribute to development of better-tolerated clinical 
regimens. The remarkable anti-tumor effect of OAd-hamIFN + Radiation suggests that it 
might be possible to reduce or eliminate chemotherapy from treatment of patients who 
cannot tolerate chemotherapy, increasing the adherence of patients to IFN-based therapy.  
There is a need for additional studies of IFN-expressing OAd as an improved IFN treatment 
modality for PDAC. IFN therapy is one of the few approaches that has been shown to 
improve both short- and long-term patient survival, and adding an IFN-expressing OAd to 
existing treatments may one day lead our field to develop an effective multimodal 
pancreatic cancer treatment. 
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12. Chapter II: Analysis of the Combination Index and therapeutic response of an 
IFN-expressing oncolytic adenovirus in combination with chemotherapy, radiation, 
and chemoradiation in human pancreatic cancer cell lines and immunodeficient mice. 
12.1. Introduction 
As mentioned in the introduction to Chapter I, the subcutaneous administration of IFN 
alpha combined with 5-FU, CDDP, and radiation in an adjuvant setting is one of the few 
therapeutic protocols that has been effective in improving the short- and long-term survival 
rates of PDAC patients (134, 135, 137, 138, 145). Compared to a two-year survival rate of 
43% after surgery and chemoradiation (135), and a five-year survival rate of 20% after 
surgery alone, treatment with IFN therapy increased patients’ two-year survival rate by 20–
41%, and their five-year survival rate by 35%. Furthermore, in the long term 28% of 
patients who reached five-year survival following treatments with IFN therapy survived at 
least ten years; nine of these patients lived more than ten years; and seven of these patients 
remain alive and show no signs of the disease (145). Aside from IFN therapy, there is no 
current alternative PDAC therapy that results in such a remarkable increase in long-term 
survival of patients. While IFN therapy has been effective in treating PDAC, its limitations 
included high IFN systemic toxicity and low levels of the cytokine in tumors, both of which 
have hampered the therapy’s full potential. Aiming to overcome these drawbacks and 
improve the efficacy of promising IFN therapy, we hypothesized that an oncolytic 
adenovirus expressing human IFN alpha (OAd-IFN) mimicking IFN therapy would 
improve the efficacy of current therapeutic regimens. Because cyclooxygenase 2 (cox-2) 
is known to be upregulated in a majority of PDAC tumors (230, 231), we included the cox-
2 promoter upstream of the E1 region of adenovirus genome since this region is responsible 
for initiating viral replication. Previous studies from our group have proven that cox-2 
controlled OAd-IFN restricted its replication to cox-2 positive PDAC cells (25, 56), and 
that treating mice bearing PDAC xenografts with OAd-IFN results in a superior anti-tumor 
effect compared to treatment with non-replicative IFN-expressing vectors both controlled 
or not controlled by cox-2 (56). To enhance OAd-IFN infectivity in PDAC cells, we also 
included a chimeric 5/3 fiber modification in the viral construct. We have shown that this 
fiber modification increases virus infectivity in a variety of PDAC cells as it shifts virus 
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tropism from the CAR receptor—which is highly deficient in PDAC cells—to desmoglein 
type 2, which has higher expression in PDAC cells than in normal cells (25). Finally, to 
potentiate OAd-IFN oncolysis and spreading in PDAC cells, and to express high levels of 
IFN in a replication-dependent manner, we deleted most of the genes in the adenovirus E3 
region and reintroduced the adenovirus death protein (ADP) and human IFN-alpha gene 
(IFN).  We have shown that these vector modifications resulted in overexpression of ADP, 
which increases vector cytotoxicity in PDAC cells, and causes time-dependent over-
expression of IFN as detected by ELISA (25, 56).  
We hypothesize that combining OAd-IFN with 5-FU, CDDP, and radiation in treatments 
mimicking IFN therapy will concentrate IFN expression in the tumor site and thereby 
enhance the cytotoxic effect of chemoradiation while reducing IFN-associated systemic 
toxicity. As discussed in Chapter I, because IFN is a chemo-radio sensitizer, concentrating 
IFN expression in the tumor site should significantly potentiate the cytotoxic effect of 
chemoradiation during therapy. Because it is well reported in the literature that using a 
replication-selective adenovirus to deliver a toxic transgene can reduce its systemic toxicity 
(232-234), we believe that expressing high concentrations of IFN focused on the tumor site 
will decrease the systemic toxicity of IFN and make more tolerable to patients. 
Although our earlier studies using an immunocompetent hamster model of pancreatic 
cancer showed that combinations of IFN-expressing oncolytic adenovirus with 5-FU, 
radiation, and 5-FU with radiation resulted in a superior anti-tumor effect and survival 
compared to group treated with chemoradiation, a more detailed understanding of how 
oncolytic adenoviruses work with chemoradiation is needed.  
Our hamster model was immunocompetent and oncolytic adenoviruses (OAd) are highly 
immunogenic. Thus, although IFN-expressing OAd combined with chemotherapy, 
radiation, and chemoradiation was synergistic in vitro, it is possible that the stimulation of 
an anti-tumor immune response contributed to an improved therapeutic effect in vivo. 
Therefore, to better assess how combinations of an IFN-expressing OAd performs in vivo, 
and exclude the interference of the immune system in the effectiveness of the therapy, we 
conducted our studies using immunodeficient mice bearing xenografts of human PDAC.  
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Because OAds do not replicate in mice and the animals were immunodeficient, treating the 
PDAC xenografts with OAd-IFN can assess how the virus actually interacts with 
chemotherapy and radiation. 
In vitro testing of OAd-IFN combined with 5-FU, radiation, and 5-FU + radiation showed 
that the combinations were moderately to highly synergistic in human PDAC cells. 
Addition of CDDP to the chemotherapy regimen (5-FU + CDDP) was shown to inhibit 
OAd-IFN, but inclusion of radiation to OAd-IFN combined with 5-FU + CDDP (OAd-IFN 
+ (5-FU+CDDP) + Radiation) abolish chemotherapy inhibition to virus, turning treatments 
highly synergistic and extremely cytotoxic in vitro and in vivo. Use of virus with the 
describe chemotherapy protocol and radiation is a close representation of IFN-therapy 
performed in clinical trials, and this treatment was the most efficacious treatment in vivo. 
As radiation was shown to override chemotherapy inhibition to the virus in vitro and in 
vivo, we tested different radiation regimens combined with OAd-IFN. We showed that 
treating tumors with radiation before infecting them with OAd-IFN enhanced the therapy’s 
anti-tumor effect. Thus, to potentiate even further the effectiveness of OAd-IFN in 
treatments that mimic IFN therapy, we suggest testing this new radiation regimen in 
therapeutic combinations that include OAd-IFN. 
Finally, because IFN induces an anti-virus effect in infected cells, we tested whether IFN 
expressed by OAd-IFN would inhibit virus replication. We showed that the expression of 
IFN by the vector (or the injection of IFN concomitantly with OAd) does not eliminate 
viral replication in PDAC tumors. Therefore, using an IFN-expressing OAd in therapies 
representing the IFN-therapy should contribute to therapy efficacy by stimulating anti-
tumor immune response through oncolysis.  
In summary, because IFN-therapy is one of the few therapeutic regimens that is effective 
in treating PDAC, developing an OAd-based IFN-therapy could result in an effective 
treatment for the disease. 
12.2. Material and methods 
Cell lines 
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The human pancreatic ductal adenocarcinoma cells Mia-Paca-2 and S2013 were obtained 
from the American Type Culture Collection (Manassas, VA). The cells were maintained in 
DMEM media supplemented with 5% Fetal Bovine Serum (FBS) and 1% 
Penicillin/Streptomycin. The cells were stored as adherent monolayers in a humidifier 
incubator at 37.8°C and 5% CO2. 
Vector structure 
Vectors used in OAd-IFN in vitro and in vivo combination therapies  
We generated a replication-competent IFN-expressing oncolytic adenovirus (OAd-IFN) 
(Figure 1) as described previously (25, 220, 235). To enhance the vector’s infectivity in 
PDAC cells, which are deficient in the CAR receptor, which is the natural receptor for an 
adenovirus (Ad) Type 5 infection, we included a chimeric 5/3 fiber. The chimeric fiber 
contains the knob of an Ad Type 3 added to the shaft of an Ad type 5 fiber. This 
modification shifts the tropism of OAd-IFN to Desmoglein-2, which is highly expressed in 
PDAC cells (24, 236). To enhance the cytotoxicity and spreading of OAd-IFN in PDAC 
cells, and to achieve replication-dependent expression of IFN-a, we deleted most of the 
nonessential genes from Ad E3 region and added the Adenovirus Death Protein (ADP) and 
human IFN-a (IFN) genes to this region (235, 237). To restrict OAd-IFN from infecting 
the PDAC cells (which have been reported to overexpress Cox-2) the Cox-2 promoter was 
added upstream of Ad E1 region because this region is responsible for initiating viral 
replication (25). We also generated Cox-2 controlled counterpart vector expressing 
luciferase (OAd-LUC) instead of IFN (Figure 1). We performed virus propagation, 
purification, storage, titration, and structure confirmation as described in previous 
publications (24, 25). 
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Figure 1. Vector structure. Structures of IFN-expressing oncolytic adenovirus (OAd-IFN), and 
counterpart vector expressing luciferase (OAd-LUC) are displayed. To restrict replicating vectors to 
PDAC cells, the Cox-2 promoter was included upstream of Adenovirus (Ad) E1 region, which is the 
region that initiates virus replication. In both vectors, we deleted most non-essential genes from Ad 
E3 region and included the Adenovirus Death Protein (ADP). In the OAd-IFN vector, we added 
human IFN-a (IFN) gene to the Ad E3 region, whereas for the OAd-LUC vector, we added the 
Luciferase gene (LUC) in place of the IFN gene. 29 
Vectors used to access replication of IFN-expressing OAd in PDAC tumors 
OAdIFN-a and OAd-Luciferase contain 5/3 fiber modification and inclusion of human 
IFN alpha or luciferase genes in Ad E3 region as described for OAd-IFN and OAd-LUC 
(Figure 1). ADP was also included in Ad E3 region as in OAd-IFN and OAd-LUC vectors. 
Adenovirus wild type promoter was kept upstream of Ad E1 region. Vectors were used to 
infect PANC-1 tumors for visualization of viral replication using confocal microscopy 
(Figure 7). Viral propagation, purification, storage, titration, and structure confirmation 
were performed as described in previous publications (24, 25).  
Combination Index analysis 
Calculation of the Combination Index (CI) to determine synergism (CI < 1), antagonism 
(CI > 1), or additive effect (CI = 1) between virus, chemotherapy, and radiation was 
performed using Compusyn software(205). The EC50 of each treatment alone (OAd-IFN, 
OAd-LUC, 5-FU, (5-FU + CDDP), and radiation) was quantitatively determined by the 
Colony Formation Assay (CFA) in S2013 and MIA-PACA-2 cells, and ED50 values were 
entered as monotherapies in Compusyn. Quantification of cytotoxicity of combination 
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treatments was determined by CFA in same cell lines, and killing effect was entered as the 
combination therapies in Compusyn. Final report with CI was generated using non-
constant ratio between therapies. Strong synergism was considered when CI < 0.5 and 
moderate synergism when CI = 0.6 to 0.9. 
In vivo experiments  
Combinations of OAd-IFN with (5-FU+ CDDP), radiation, and (5-FU+ CDDP) + 
radiation  
MIA-PACA-2 cells (2 x 106) suspended in 100 µl of PBS were subcutaneously injected 
into both hind legs of 6-8 weeks old female athymic nude mice obtained from Charles 
River Laboratories. Animals were divided in 8 groups with 7 tumors per group. When one 
of tumor’s diameters reached 8 - 10 mm, they were injected with 1 x 1010 VP OAd-IFN 
diluted in 50 µl PBS. The day of virus injection was considered as Day 0. Intraperitoneal 
injections of 20 mg/kg 5-FU were given on days 2, 4, 5, 6, and CDDP was given on day 2 
only. Radiation groups had tumors irradiated on day 2 at the same shortly after 
administration of the first dose of 5-FU and CDDP (Figure 6).  Previous to 4Gy irradiation, 
animals were anesthetized with 100 mg/kg Ketamine and 15 mg/kg Xylazine and placed 
in customized radiation chamber where tumors were exposed to radiation while the 
animal’s bodies were protected with lead shield. Tumor diameter was measured two times 
per week using calipers. Tumor volume was calculated considering tumor volume = 
(width2 × length)/2. The animals were euthanized according to IACUC guidelines when 
one of the tumor’s diameters was bigger than 20mm. 
Assessment of OAd-IFN replication in PDAC tumors 
PANC-1 cells (5 x 106) suspended in 100 µl of PBS, and were subcutaneously injected into 
both hind legs of 6-8 weeks old female athymic nude mice obtained from Charles River 
Laboratories. Animals were divided in 4 groups with 8 tumors per group. When one of 
tumor’s diameters reached 6-8 mm, they were injected with 1 x 1010 VP of OAdIFN-a or 
OAd-Luciferase diluted in 50 µl PBS (Figure 7). Groups treated with OAd-Luciferase + 
Type I IFN had 60 Units/g of body weight of IFN injected intratumorally one day after 
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injection with OAd-Luciferase. After seven days, animals were euthanized according to 
IACUC guidelines and tumors were harvested and stored at -80°C. Tumors were stained 
with anti-hexon FITC labelled antibodies, and presence of hexon protein was visualized 
using confocal microscopy.  
Statistical analysis 
We used the SAS proc mixed program to generate a fit linear mixed model to analyze tumor 
growth/time. The log of absolute tumor volume was considered as the outcome variable, 
and the treatment group, time (continuous), and their interaction were considered as the 
predictor variables. The analysis included random effects to account for the correlation 
among repeated measurements in each tumor. The primary hypothesis we tested was 
whether the time trend, or slopes of each trend line differed among the groups. When the 
tumor volume was 0, its log volume was defined as “1” during the analysis. Because the 
chemoradiation group was the reference group used in the IFN-therapy clinical trials, the 
group we treated with (5-FU + CDDP) + radiation was the internal control group in the 
experiments (Figure 6A). In Figure 6B, combination of OAd-IFN with 5-FU+CDDP was 
the comparison group. 
12.3. Results 
Establishing monotherapy EC50 
To assess the Combination Index (CI) between OAd-IFN and the therapeutic used in IFN-
therapy using Compusyn, and to choose the doses of combined therapeutics in later 
experiments, we established the ED50 of OAd-IFN, 5-FU, and radiation as monotherapies 
using the Colony Formation Assay in the S2013 and MIA-PACA-2 PDAC cell lines 
(Figure 2). I used CFA because it is the gold standard assay to evaluate the effectiveness 
of radiation in vitro. We included a non-IFN expressing counterpart vector (OAd-LUC) in 
the assessment because we wanted to evaluate how much IFN contributed to the CI analysis 
and the cytotoxicity of the therapy in experiments that compared combinations of OAd-
IFN and OAd-LUC with monotherapies. When comparing the two PDAC cell lines, S3013 
was more sensitive to all the tested monotherapies. After determining the ED50 of each 
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drug, we chose to use the lowest and least effective doses of each monotherapy in 
combination studies in later experiments. 
 
Figure 2. Establishing monotherapy ED50 in Colony Formation Assay. We tested a range of 
doses of OAd-IFN, OAd-LUC, 5-FU, and radiation in MIA-PACA-2 and S2013 PDAC cells. The data 
shows that S2013 is slightly more sensitive to monotherapies than MIA-PACA-2. The numbers on 
top of the histogram bars reflect the percentage of colonies that formed after each monotherapy 
treatment.30 
IFN expressed by OAd-IFN contributes to stronger cytotoxicity and synergism in 
OAd-IFN combinations with chemotherapy, radiation, and chemoradiation 
By using ED50s values for S2013, and the killing effect of OAd-IFN combined with 5-FU, 
radiation, and 5-FU + radiation in CFA, we used Compusyn to calculate the Combination 
Index (CI) of the OAd-IFN treatments (Figure 3). I focused on S2013 to more thoroughly 
evaluate the CI because this cell line is more sensitive monotherapies, having the potential 
to clearly reflect the interaction between the therapy components. Comparisons of colony-
formation inhibition in combinations of OAd-LUC—a counterpart vector not expressing 
IFN—and OAd-IFN combined with radiation showed that IFN expressed by OAd-IFN 
induced a higher level of cytotoxicity or colony-formation inhibition in the treatments 
(Figure 3A and B). The synergism (CI<1) between OAd-IFN and lower doses of radiation 
was stronger than the synergism in combinations of OAd-LUC with same radiation dose. 
Although an increase in the dose of radiation in combination with both OAd-IFN and OAd-
LUC resulted in more cytotoxic treatments, the combination index was driven towards a 
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more additive (CI=1) or antagonistic interaction (CI>1) between the virus and the radiation, 
showing increase of radiation dose during therapy have the potential to decrease therapy 
efficacy. Treatments of OAd-LUC or OAd-IFN combined with 5-FU (Figure 3C and D) 
showed that, while combinations including OAd-LUC were antagonistic and less 
cytotoxic, combinations with OAd-IFN were highly synergistic and strongly cytotoxic. 
This data highlight that IFN expressed by the vector greatly contributed to improved 
cytotoxicity and enhanced the synergism between the virus and the chemotherapy. Because 
the historic comparison control used in IFN-therapy was 5-FU + radiation, we analyzed the 
CI and cytotoxicity of 5-FU combined with radiation (Figure 3G). These combinations 
were moderately synergistic and highly cytotoxic, especially when we used higher doses 
of chemoradiation. Finally, comparisons between OAd-LUC and OAd-IFN in treatment 
that mimicked IFN-therapy (OAd-IFN + 5-FU + radiation) (Figure 3. E and F) showed 
that IFN expressed by the virus contributed to more synergistic and cytotoxic 
combinations, especially when very low doses of OAd-IFN (0.5 VP/cell) and radiation 
(2Gy) were combined.  
In summary, this data highlight that the synergistic interaction between OAd-IFN and the 
drugs used in IFN-therapy show that the virus has great potential to reduce therapy toxicity 
because it allows doctors to reduce the doses of the therapeutics used together while 
maintaining or enhancing their efficacy. 
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Figure 3. IFN contribution to cytotoxicity and synergistic interaction between OAd-IFN and 
chemotherapy, radiation, and chemoradiation. Displayed is an analysis of Combination Index 
(CI) of OAd-IFN combination in S2013 using colony formation assay. Combinations of OAd-LUC 
(A) or OAd-IFN (B) and radiation shows that IFN expressed by OAd-IFN potentiates synergism 
when low dose of radiation is used. Combinations of OAd-LUC with chemotherapy results in 
antagonism (C), while combinations of OAd-IFN with same chemotherapy doses were highly 
synergistic (D). (E) Use of OAd-LUC in treatments that mimic IFN-therapy (virus combined with 
chemoradiation) were additive (CI=1) or moderately synergistic (CI=0.98), while use of OAd-IFN in 
same therapeutic set-up resulted in synergism with any of the radiation and chemotherapy doses 
tested (F). As 5-FU in combination with radiation was the reference therapy used to compare 
effectiveness of IFN-therapy in clinical trials, we decided to test this therapeutic regimen. Data 
showed that combinations of 5-FU and radiation were highly cytotoxic and synergistic (G). (CI<1) 
synergism, (CI=1) additive effect, and (CI>1) antagonism. The numbers on top of the histogram 
bars reflect the percentage of colonies that formed after each monotherapy treatment.  
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Effect of radiation in OAd-IFN combinations tested in PDAC cell line used in pre-
clinical model 
Because an increase in the dose of radiation in OAd-IFN combinations resulted in less 
synergistic Combination Indexes (CI) in the S2013 PDAC cell line (Figure 3B), we used 
CFA to assess whether the same was true for MIA-PACA-2, the PDAC cell line we used to 
establish xenografts in our pre-clinical model. Comparisons between combinations of 
OAd-LUC and OAd-IFN with radiation showed that, although an increase in the dose of 
radiation in OAd-LUC combinations resulted in a less cytotoxic and a more antagonistic 
(CI=0.66 versus CI = 1.31) treatments (Figure 4A), the OAd-IFN combinations became 
more cytotoxic and synergistic (CI=0.5 versus CI=0.35) when the dose of radiation 
increased. (Figure 4B). This data confirmed that, in the case of the MIA-PACA-2 cell line 
(which was less susceptible to radiation and OAd-IFN when each were used as 
monotherapies (Figure 2)), IFN expressed by OAd-IFN could potentiate effect of 
radiation. Our analysis of the CI in treatments using combinations of 5-FU and radiation 
showed that an increase in the dose of radiation resulted in a more antagonistic CI (CI=0.95 
versus CI=1.25), which diminished the cytotoxic effect (Figure 4C). Comparisons of OAd-
LUC and OAd-IFN in treatments that mimicked IFN-therapy (IFN + 5-FU + Radiation) 
showed that, although an increase in the dose radiation makes combinations of 5-FU + 
radiation antagonistic, the IFN expressed by the virus overcame this antagonistic 
interaction and made combinations of OAd-IFN + 5-FU + Radiation highly synergistic and 
cytotoxic (Figure 4D). These data support including an IFN-expressing OAd in treatments 
that mimic IFN-therapy. Using OAd-IFN consistently potentiates the effect of 
chemoradiation and improved the efficacy of therapy. If an IFN-expressing OAd is 
included in IFN-therapy protocols, the synergistic interaction between the virus and 
therapeutic components can reduce the amounts of chemoradiation dose and contribute to 
a less toxic treatment. 
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Figure 4. Effect of radiation on OAd-IFN combinations tested in cell lines used in the pre-
clinical model of PDAC. Displayed is the effect of radiation in combination with OAd-IFN using 
colony formation in the MIA-PACA-2 PDAC cell line. This cell line is used to form human PDAC 
xenografts in nude mice. CFA output shows that while combinations of OAd-LUC with low doses of 
radiation were synergistic (CI=0.66), increase of dose of radiation in combination with virus 
abolished synergistic interaction (CI=1.31) (B). On the other hand, use of OAd-IFN with either low 
or high doses of radiation were both highly synergistic (CI=0.5 and CI=0.35) (C). (D) Combinations 
of either OAd-LUC or OAd-IFN in treatment protocol mimicking IFN-therapy (IFN + 5-FU + 
Radiation) were highly synergistic when low doses of therapeutics were used, but only 
combinations of OAd-IFN with higher doses of chemotherapy or radiation were highly synergistic. 
The numbers on top of the histogram bars reflect the percentage of colonies formed after treatment. 
(CI<1) synergism, (CI=1) additive effect, and (CI>1) antagonism. 31 
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Use of radiation with combinations of OAd-IFN and 5-FU + CDDP results in highly 
cytocidal and synergistic combinations 
In the first stage of IFN-therapy, patients are exposed to one bolus dose of CDDP, 
continuous administration of 5-FU, and fractionated radiation (Figure 5A). After we 
confirmed that OAd-IFN can synergistically potentiate the killing effect of 5-FU and 
radiation, we decided to assess if the same effect occurred when OAd-IFN was combined 
with CDDP + 5-FU or with CDDP + 5-FU and radiation (Figure 5).  
We performed the CFA in MIA-PACA-2 PDAC cells and calculated the CI. Because earlier 
experiments showed that combinations of OAd-IFN with 2 and 4Gy of radiation were 
synergistic (Figures 3 and 4), we decided to lower the radiation doses to 1 and 2GY in this 
assay (Figure 5). Because we want to use OAd-IFN to reduce the toxicity of therapy, it 
was necessary to study the efficacy of combinations of very low doses of therapeutics. 
We first assessed the killing effect of 5-FU combined with CDDP, and later evaluated the 
cytotoxic effect and CI of CDDP + 5-FU combined with radiation. The data showed that 
combinations of chemotherapy drugs and low doses of radiation were moderately 
cytotoxic, and that the cytotoxicity increased when we used higher doses of therapeutics 
(Figure 5B). Nevertheless, the CI for both treatments were antagonistic, and we observed 
higher antagonism when we combined higher doses of chemotherapy and radiation. 
Treatments of OAd-LUC and 5-FU + CDDP were antagonistic, and we observed extreme 
antagonism when we used low doses of the virus and chemotherapy. This antagonism 
translates to a diminished killing effect in OAd-LUC combined with lower or higher doses 
of therapeutics (Figure 5C). OAd-IFN in combination with CDDP + 5-FU also was 
antagonistic. Although combinations with OAd-IFN were less antagonistic and more 
cytotoxic compared to combinations with OAd-LUC, the killing effect was also effected 
by treatment with 5-FU + CDDP (Figure 5D). Despite this result, using either OAd-LUC 
or OAd-IFN in combination with 5-FU + CDDP and radiation were highly cytotoxic and 
synergistic (Figure 5E). This data demonstrated that addition of radiation to treatment 
regimen overruled viral antagonism, turning the treatment regimen highly effective in 
killing PDAC cells. 
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Figure 5. Using radiation with combinations of OAd-IFN with 5-FU + CDDP results 
in highly cytotoxic and synergistic combinations. To better replicate the IFN-therapy 
used to treat PDAC patients in clinical trials (A), we used CFA in MIA-PACA-2 to assess 
the CI and cytotoxicity of OAd-IFN combined with (5-FU + CDDP), and radiation. (B) 
Combinations of CDDP + 5-FU with radiation show that although two chemotherapy doses 
are used in combination with radiation, these combinations are antagonistic (CI>1). 
Combinations of either OAd-LUC (C) or OAd-IFN (D) with (5-FU + CDDP) were all 
shown to be antagonistic (CI>1), but very strong antagonism was only shown when low 
doses of non-IFN expressing OAd (OAd-LUC) was combined with 
Treating mice with OAd-IFN in combinations that mimic IFN therapy results in 
reduced tumor growth 
To test the efficacy of OAd-IFN in combinations that mimic IFN therapy, and to assess the 
interaction between OAd-IFN and therapeutics used in this therapy, we treated nude mice 
bearing MIA-PACA-2 xenografts with OAd-IFN combinations representing IFN-therapy 
(Figure 6). To better replicate IFN-therapy in clinical trials (Figure 5A), we chose 5-FU + 
CDDP as our chemotherapy regimen, and treatment with 5-FU + CDDP combined with 
radiation (chemoradiation) as our control group. Experimental results showed that 
compared to the control chemoradiation group, the groups treated with OAd-IFN combined 
with radiation, or OAd-IFN combined with 5-FU + CDDP and radiation showed the 
strongest anti-tumor effect, while combination of OAd-IFn with 5-FU + CDDP were less 
efffective (Figure 6A). After Day 9 of the treatment, the tumors treated with OAd-IFN in 
combination with 5-FU + CDDP presented exponential growth, and this treatment was 
weaker than treatment with OAd-IFN alone. This result suggests that the antagonism we 
observed in combinations of OAd-IFN and 5-FU + CDDP in vitro (Figure 5C) had 
translated to a diminished therapeutic effect in vivo. The tumor-growth rate (TGR), or 
percent of tumor growth/day, of the tumors in the chemoradiation group and the groups 
treated with OAd-IFN combined with chemotherapy, radiation, or chemoradiation were 
respectively 3.6%, 9%, 6.9%, and 0.6%. The TGR data showed that, although the 
treatments with OAd-IFN combinations did not reduce the tumor growth compared with 
the chemoradiation group, combinations of the virus with radiation or with 5-FU + CDDP 
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and radiation increased tumor debulking, resulting in smaller tumors throughout the 
treatment. However, despite the fact tumor volumes in the group treated with OAd-IFN + 
Radiation were smaller, the TGR in this group was 6.9%, which was higher than the TGR 
in control chemoradiation group (TGR=3.6%). This might have happened because the 
average tumor volume in the group treated with OAd-IFN + Radiation was smaller in the 
beginning of the experiment. The average tumor volume consisted of the average of all 
tumor volumes presented that group, and this was the value used to plot each time point in 
the graph represented in Figure 6A. Thus, although tumors in the OAd-IFN + Radiation 
group randomly included a variety of tumors (larger and smaller) just as the other treatment 
groups, tumors that were smaller might have responded better to the therapy.   
Although the efficacy of OAd-IFN in combination chemoradiation was high throughout 
most of the experiment, some tumors in this group showed exponential growth by Day 18, 
and this growth largely contributed to the accentuated increase in the average tumor volume 
value for this group by the end of the experiment (Figure 6A). While this exponential 
tumor growth looked detrimental to therapy efficacy, two tumors in this group (OAd-IFN 
+ (5-FU + CDDP) + Radiation) showed complete remission. This observation shows that 
there was variability in the therapeutic effect of this therapy. Nevertheless, the accelerated 
tumor growth of some tumors does not invalidate the effectiveness of this therapy as use 
of OAd-IFN combined with chemoradiation (OAd-IFN + (5-FU + CDDP) + Radiation) 
was the only treatment regimen capable of considerably decrease the tumor growth rate of 
tumors (TGR=0.6%). I speculate that because this treatment includes OAd-IFN combined 
with 5-FU + CDDP, and this chemotherapy regimen was shown to antagonize OAd-IFN, 
antagonism to the virus contributed to accelerated tumors growth of some tumors. It is also 
possible that repeated administration of the virus during therapy would have abolished this 
variable therapeutic effect. It is widely known that virotherapies usually employ repeated 
administration of viruses in the treatment of cancer(11).  
The least effective therapy in this study were OAd-IFN (TGR= 6.1%), 5-FU + CDDP 
(TGR=8.7), and OAd-IFN + (5-FU + CDDP) (TGR=9%). As viral only treated group 
showed a TGR of 6.1%, this data reinforced that use of 5-FU + CDDP in combination with 
OAd-IFN (TGR=9%) severely impacted OAd-IFN effectivity.  
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To determine whether we could reproduce this result, and to rule out the fact that the 
variation in the average tumor volume in the beginning of the experiment contributed to 
therapeutic effect, we conducted another experiment to test the efficacy of all the viral 
combinations (Figure 6B). Experiment output showed that combination of OAd-IFN with 
5-FU + CDDP was the worst viral combination therapy in the study (TGR=6%), confirming 
this chemotherapy regimen might hamper effectiveness of therapy. Data also showed that 
treatments with OAd-IFN in combination with radiation or chemoradiation were effective 
in keeping tumor volume low (respective TGR of 2% and 0.4%). Consistent with our 
previous study, treatment with OAd-IFN + (5-FU + CDDP) + radiation was the most 
effective therapy (TGR=0.4%) in the study. Therefore, we concluded that although 
variation in initial tumor volume might have played a role in variability of therapeutic effect 
in the first experiment (Figure 6A), combinations of OAd-IFN with radiation or 
chemoradiation were still highly effective therapies when initial tumor volume was 
uniform (Figure 6B).  
In summary, our data support including an IFN-expressing OAd in combination with 
chemoradiation regiments that mimic IFN therapy. Although we observed antagonism 
between the virus and the chemotherapies used, adding radiation to the therapy regimen 
appeared to surmount the antagonism and make the therapy effective. 
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Figure 6. Therapeutic effect of OAd-IFN combinations in nude mice. Nude mice bearing MIA-
PACA-2 PDAC cell xenografts were treated with OAd-IFN combinations. To better replicate IFN-
therapy in clinical trials, the chemotherapy regimen consisted of 5-FU + CDDP. Tumor Growth Rate 
(TGR), or the amount (%) of tumor volume increase/day was used to compare therapy groups. (A) 
Compared to the control-therapy group (5-FU + CDDP) + radiation (TGR = 3.6%), treating animals 
with OAd-IFN + radiation (TGR=6.9) or OAd-IFN + (5-FU + CDDP) + Radiation (TGR=0.6%) 
resulted in the most effective therapies to decrease tumor volume over time. Compared to group 
treated with OAd-IFN (TGR=6.1%), group treated with OAd-IFN + (5-FU + CDDP) (TGR=9%) had 
the anti-tumor effect suppressed. However, inclusion of radiation to treatment regimen (OAd-IFN + 
(5-FU + CDDP) + Radiation) abolished virus antagonism by chemotherapy, resulting in the most 
effective therapy in the study (TGR=0.6%) (B) To confirm if adding 5-FU + CDDP to OAd-IFN 
treatments affected treatment efficacy,  and if variation in initial tumor volume impacted therapeutic 
effect of therapies, we repeated the experiment testing OAd-IFN combinations with 5-FU + CDDP, 
radiation, and (5-FU + CDDP) + Radiation. Data confirmed that using 5-FU + CDDP with OAd-IFN 
strongly inhibited the virus (TGR=6.6%), and that combinations of OAd-IFN with radiation 
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(TGR=2%) and chemoradiation (TGR=0.4%) showed the strongest anti-tumor effect. Again, use of 
virus in combinations closely resembling IFN-Therapy in clinical trials (OAd-IFN + (5-FU + CDDP) 
+ Radiation) resulted in the best therapy to inhibit tumor growth.  The graph shows the absolute 
tumor volume over time. 
IFN expression by OAd or combination of OAd with universal IFN does not affect 
viral replication 
IFN is known to induce an antiviral state in cells that will limit viral infection. To assess 
whether IFN expression by an OAd can restrict its own replication, we compared the 
replication of an IFN-expressing OAd (OAdIFN-a) with the replication of a non-IFN 
expressing OAd (OAd-Luciferase) in PANC-1 xenografts (Figure 7A and B). We assessed 
OAd replication by using confocal microscopy and FITC staining of the adenovirus hexon 
protein, which is a structural protein encoded during OAd late gene expression. The data 
showed that, just like an OAd that does not express IFN (Figure 7A), IFN-expressing OAd 
could replicate in PDAC xenografts (Figure 7B).  
To replicate IFN-therapy, we injected 60U/g body weight of Universal type I IFN (type I 
IFN) into the tumor after infecting it with OAd-Luciferase (Figure 7C). We used universal 
type I IFN because the action of IFN is species-specific (119) and universal type I IFN is 
effective in multiple animal species. The Type I IFN dose we used was equivalent to the 
IFN dose used to treat patients in IFN-therapy. Our assessment of OAd-Luciferase 
replication showed that the virus could replicate even when IFN was present intratumorally.  
Thus, these data corroborated our conclusion that although IFN has the potential to inhibit 
viral replication in infected cells, expression of IFN by OAd does not inhibit OAd 
replication in tumors. Therefore, using IFN-expressing OAd to treat PDAC should combine 
the vector’s oncolytic potential with the anti-tumor effect of IFN during therapy. 
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Figure 7. Effect of IFN expressed by OAd in viral replication. We assessed OAd replication in 
nude mice bearing xenografts of PANC-1 PDAC cells. Confocal images of viral replication show 
the FITC staining of the adenoviral hexon capsid protein. Comparisons of viral replication between 
a non-IFN expressing OAd (OAd-Luciferase) (A), and an IFN-expressing OAd (OAdIFN-a) (B) 
show that both viruses are able to replicate in tumors, and although OAdIFN-a expresses an 
antiviral cytokine, the virus can still replicate in tumors. Combining type I IFN with OAd-Luciferase 
(C) confirms that IFN does not inhibit viral replication. Tumors were stained seven days post 
infection with the virus. 32 
Effect of radiation timing on OAd-IFN combinations in vivo 
Our analysis of the in vitro and in vivo data clearly shows that adding radiation to 
combinations of OAd-IFN + (5-FU + CDDP) overrules chemotherapy’s antagonistic effect 
on the virus and improves the virus’ efficacy when used in triple combination (OAd-IFN + 
(5-FU + CDDP) + radiation). To determine if changing the timing of the radiation can 
enhance the efficacy of OAd-IFN combinations with radiation, and to potentially improve 
the therapeutic effect of the triple combination, we tested different radiation schedules in 
combination with OAd-IFN. We performed the study in mice bearing MIA-PACA-2 
tumors and assessed the relative growth of the tumors (Figure 8). We used the group treated 
with OAd-IFN + 4GY as our reference group because this was the treatment protocol used 
in our earlier in vivo experiments (Figure 6). Because IFN is a radiosensitizer, in this group 
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we attempted to concentrate the virus’ IFN expression in tumors before administering the 
radiation (4GY). This strategy not only reflects the treatment protocol in IFN therapy, but 
also potentiates the radiation effect in tumor cells. The data show that administering 
unfractionated (4Gy) or fractionated (2GY + 2GY) radiation before infecting the tumor 
with the virus resulted in the study’s most effective treatment protocols.  
Compared to the tumor-growth rate (TGR) in the reference therapy (TGR=9.6%), using 
unfractionated radiation (4Gy + OAd-IFN) or fractionated radiation ((2Gy + 2Gy) + OAd-
IFN) before infecting the tumor with the virus resulted in the greatest tumor growth 
inhibition (TGR=2%, p < 0.01; and TGR=6%, p=0.08, respectively). Between these two 
radiation regimens, administering a full radiation dose (4Gy) before treatment with OAd-
IFN was more efficacious because it induced complete remission in two tumors and 
markedly hampered tumor growth in early stages of the therapy. The least effective 
radiation schedule was the administration of fractionated radiation after infecting the tumor 
with OAd-IFN (OAd-IFN + (2Gy + 2Gy)) (TGR= 7.9%, p=0.4). These data demonstrated 
that the effectiveness of therapy is significantly diminished if radiation insult after virus 
infection is weaker. This observation is consistent with our in vitro CFA data (Figure 5), 
which showed that an increase in the dose of radiation after OAd-IFN infection enhances 
the synergistic and cytotoxic effect of treatments in MIA-PACA-2 cells. In summary, we 
suggest that to enhance the anti-tumor effect therapies mimicking IFN therapy (OAd-IFN 
+ (5-FU + CDDP) + Radiation), a radiation schedule where the radiation is administered 
before the OAd-IFN infection should be explored. This new therapeutic approach might 
enhance the effectiveness of OAd-IFN in combination with chemoradiation and diminish 
the variability of efficacy when tumors are treated with OAd-IFN in combination with 5-
FU + CDDP and radiation.  
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Figure 8. Effect of radiation timing on OAd-IFN combinations. To assess if modifying radiation 
timing can enhance the efficacy of combinations of OAd-IFN with radiation, we tested different 
radiation schedules in combination with OAd-IFN in mice bearing Mia-Paca-2 tumors. The 
experiment’s control group was OAd-IFN + 4Gy (1), which consisted of infecting the tumors with 
OAd-IFN before radiation. This was the same radiation protocol we used in earlier in vivo 
experiments (Figure 6). Tumor Growth Rate (TGR), or the amount (%) of tumor volume 
increase/day was used to compare therapy groups. (A) Radiation schedule in OAd-IFN treatments. 
(B) Data showed that using full radiation dose (4GY + OAd-IFN (2); TGR=0.2%) or fractionated 
radiation ((2Gy + 2GY) + OAd-IFN (4); TGR=6.6%) before infecting the tumors with OAd-IFN 
resulted in the study’s most effective therapies with the strongest anti-tumor effects. Compared to 
the reference therapy (OAd-IFN + 4Gy (1), TGR=9.6%), use of fractionated radiation after virus 
infection (OAd-IFN +2Gy + 2Gy (3); TGR=7.9%) was the least effective treatment regimen. This 
showed that in case radiation is administered after viral infection, higher dose of radiation should 
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be considered. The graph displays the relative volume of the tumors, which reflects the tumor-
growth rate over time. Graph was plotted using geometric mean of the average relative tumor 
volume.33 
12.4. Figures 
 
Figure 1. Vector structure. Structures of IFN-expressing oncolytic adenovirus (OAd-IFN), and 
counterpart vector expressing luciferase (OAd-LUC) are displayed. To restrict replicating vectors to 
PDAC cells, the Cox-2 promoter was included upstream of Adenovirus (Ad) E1 region, which is the 
region that initiates virus replication. In both vectors, we deleted most non-essential genes from Ad 
E3 region and included the Adenovirus Death Protein (ADP). In the OAd-IFN vector, we added 
human IFN-a (IFN) gene to the Ad E3 region, whereas for the OAd-LUC vector, we added the 
Luciferase gene (LUC) in place of the IFN gene. 34 
 
Figure 2. Establishing monotherapy ED50 in Colony Formation Assay. We tested a range of 
doses of OAd-IFN, OAd-LUC, 5-FU, and radiation in MIA-PACA-2 and S2013 PDAC cells. The data 
shows that S2013 is slightly more sensitive to monotherapies than MIA-PACA-2. The numbers on 
top of the histogram bars reflect the percentage of colonies that formed after each monotherapy 
treatment.35 
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Figure 3. IFN contribution to cytotoxicity and synergistic interaction between OAd-IFN and 
chemotherapy, radiation, and chemoradiation. Displayed is an analysis of Combination Index 
(CI) of OAd-IFN combination in S2013 using colony formation assay. Combinations of OAd-LUC 
(A) or OAd-IFN (B) and radiation shows that IFN expressed by OAd-IFN potentiates synergism 
when low dose of radiation is used. Combinations of OAd-LUC with chemotherapy results in 
antagonism (C), while combinations of OAd-IFN with same chemotherapy doses were highly 
synergistic (D). (E) Use of OAd-LUC in treatments that mimic IFN-therapy (virus combined with 
chemoradiation) were additive (CI=1) or moderately synergistic (CI=0.98), while use of OAd-IFN in 
same therapeutic set-up resulted in synergism with any of the radiation and chemotherapy doses 
tested (F). As 5-FU in combination with radiation was the reference therapy used to compare 
effectiveness of IFN-therapy in clinical trials, we decided to test this therapeutic regimen. Data 
showed that combinations of 5-FU and radiation were highly cytotoxic and synergistic (G). (CI<1) 
synergism, (CI=1) additive effect, and (CI>1) antagonism. The numbers on top of the histogram 
bars reflect the percentage of colonies that formed after each monotherapy treatment.  
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Figure 4. Effect of radiation on OAd-IFN combinations tested in cell lines used in the pre-
clinical model of PDAC. Displayed is the effect of radiation in combination with OAd-IFN using 
colony formation in the MIA-PACA-2 PDAC cell line. This cell line is used to form human PDAC 
xenografts in nude mice. CFA output shows that while combinations of OAd-LUC with low doses of 
radiation were synergistic (CI=0.66), increase of dose of radiation in combination with virus 
abolished synergistic interaction (CI=1.31) (B). On the other hand, use of OAd-IFN with either low 
or high doses of radiation were both highly synergistic (CI=0.5 and CI=0.35) (C). (D) Combinations 
of either OAd-LUC or OAd-IFN in treatment protocol mimicking IFN-therapy (IFN + 5-FU + 
Radiation) were highly synergistic when low doses of therapeutics were used, but only 
combinations of OAd-IFN with higher doses of chemotherapy or radiation were highly synergistic. 
The numbers on top of the histogram bars reflect the percentage of colonies formed after treatment. 
(CI<1) synergism, (CI=1) additive effect, and (CI>1) antagonism. 36 
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Figure 5. Using radiation with combinations of OAd-IFN with 5-FU + CDDP results in highly 
cytotoxic and synergistic combinations. To better replicate the IFN-therapy used to treat PDAC 
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patients in clinical trials (A), we used CFA in MIA-PACA-2 to assess the CI and cytotoxicity of OAd-
IFN combined with (5-FU + CDDP), and radiation. (B) Combinations of CDDP + 5-FU with radiation 
show that although two chemotherapy doses are used in combination with radiation, these 
combinations are antagonistic (CI>1). Combinations of either OAd-LUC (C) or OAd-IFN (D) with 
(5-FU + CDDP) were all shown to be antagonistic (CI>1), but very strong antagonism was only 
shown when low doses of non-IFN expressing OAd (OAd-LUC) was combined with 
chemotherapies (CI=42) (C).   Despite antagonism between chemotherapies and OAds, and 
between chemotherapies and radiation, inclusion of radiation to OAd treatment (OAd-IFN + (5-FU 
+ CDDP) + Radiation) or (OAd-LUC + (5-FU + CDDP) + Radiation) resulted in highly synergistic 
and cytotoxic treatments. Very stronger synergism (CI<0.3) was specially observed in combinations 
including OAd-IFN (E). (CI<1) synergism, (CI=1) additive effect, and (CI>1) antagonism. Numbers 
on top of the histogram bars reflect the percentage of colonies formed after treatment.37 
 
Figure 6. Therapeutic effect of OAd-IFN combinations in nude mice. Nude mice bearing MIA-
PACA-2 PDAC cell xenografts were treated with OAd-IFN combinations. To better replicate IFN-
therapy in clinical trials, the chemotherapy regimen consisted of 5-FU + CDDP. Tumor Growth Rate 
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(TGR), or the amount (%) of tumor volume increase/day was used to compare therapy groups. (A) 
Compared to the control-therapy group (5-FU + CDDP) + radiation (TGR = 3.6%), treating animals 
with OAd-IFN + radiation (TGR=6.9) or OAd-IFN + (5-FU + CDDP) + Radiation (TGR=0.6%) 
resulted in the most effective therapies to decrease tumor volume over time. Compared to group 
treated with OAd-IFN (TGR=6.1%), group treated with OAd-IFN + (5-FU + CDDP) (TGR=9%) had 
the anti-tumor effect suppressed. However, inclusion of radiation to treatment regimen (OAd-IFN + 
(5-FU + CDDP) + Radiation) abolished virus antagonism by chemotherapy, resulting in the most 
effective therapy in the study (TGR=0.6%) (B) To confirm if adding 5-FU + CDDP to OAd-IFN 
treatments affected treatment efficacy,  and if variation in initial tumor volume impacted therapeutic 
effect of therapies, we repeated the experiment testing OAd-IFN combinations with 5-FU + CDDP, 
radiation, and (5-FU + CDDP) + Radiation. Data confirmed that using 5-FU + CDDP with OAd-IFN 
strongly inhibited the virus (TGR=6.6%), and that combinations of OAd-IFN with radiation 
(TGR=2%) and chemoradiation (TGR=0.4%) showed the strongest anti-tumor effect. Again, use of 
virus in combinations closely resembling IFN-Therapy in clinical trials (OAd-IFN + (5-FU + CDDP) 
+ Radiation) resulted in the best therapy to inhibit tumor growth.  The graph shows the absolute 
tumor volume over time. 
 
Figure 7. Effect of IFN expressed by OAd in viral replication. We assessed OAd replication in 
nude mice bearing xenografts of PANC-1 PDAC cells. Confocal images of viral replication show 
the FITC staining of the adenoviral hexon capsid protein. Comparisons of viral replication between 
a non-IFN expressing OAd (OAd-Luciferase) (A), and an IFN-expressing OAd (OAdIFN-a) (B) 
show that both viruses are able to replicate in tumors, and although OAdIFN-a expresses an 
antiviral cytokine, the virus can still replicate in tumors. Combining type I IFN with OAd-Luciferase 
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(C) confirms that IFN does not inhibit viral replication. Tumors were stained seven days post 
infection with the virus. 38 
 
Figure 8. Effect of radiation timing on OAd-IFN combinations. To assess if modifying radiation 
timing can enhance the efficacy of combinations of OAd-IFN with radiation, we tested different 
radiation schedules in combination with OAd-IFN in mice bearing Mia-Paca-2 tumors. The 
experiment’s control group was OAd-IFN + 4Gy (1), which consisted of infecting the tumors with 
OAd-IFN before radiation. This was the same radiation protocol we used in earlier in vivo 
experiments (Figure 6). Tumor Growth Rate (TGR), or the amount (%) of tumor volume 
increase/day was used to compare therapy groups. (A) Radiation schedule in OAd-IFN treatments. 
(B) Data showed that using full radiation dose (4GY + OAd-IFN (2); TGR=0.2%) or fractionated 
radiation ((2Gy + 2GY) + OAd-IFN (4); TGR=6.6%) before infecting the tumors with OAd-IFN 
resulted in the study’s most effective therapies with the strongest anti-tumor effects. Compared to 
the reference therapy (OAd-IFN + 4Gy (1), TGR=9.6%), use of fractionated radiation after virus 
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infection (OAd-IFN +2Gy + 2Gy (3); TGR=7.9%) was the least effective treatment regimen. This 
showed that in case radiation is administered after viral infection, higher dose of radiation should 
be considered. The graph displays the relative volume of the tumors, which reflects the tumor-
growth rate over time. Graph was plotted using geometric mean of the average relative tumor 
volume.39 
12.5. Discussion 
Using IFN-a in combination with 5-FU, CDDP, and radiation in an adjuvant setting has 
been highly effective in improving the short- and long-term survival of PDAC patients 
(134, 135, 145, 149). Although efficacious, the potential of this therapy is negatively 
affected by IFN-associated systemic toxicity and low intratumoral levels of IFN. To 
improve one of the few known effective therapeutic regimens for treating PDAC, we tested 
the use of IFN-expressing oncolytic adenovirus (OAd-IFN) in combination with 
chemoradiation in regimens that mimic IFN therapy in clinical trials.  
The data showed that combinations of OAd-IFN with 5-FU, radiation, and 5-FU + radiation 
were synergistic and highly effective in killing PDAC cells in vitro (Figures 3 and 4). 
Testing CDDP and 5-FU combination chemotherapy (5-FU + CDDP) with OAd-IFN 
demonstrated that chemotherapies are antagonistic to the virus (Figure 5). Despite that, we 
demonstrated that inclusion of radiation to combinations with OAd-IFN and (5-FU + 
CDDP) eliminated the antagonism created by the chemotherapies resulting in highly 
cytotoxic and synergistic treatments in vitro (Figure 5). We also showed that 5-FU + CDDP 
antagonism to OAd-IFN was also observed in vivo, but addition of radiation to therapy 
eradicated chemotherapy antagonism to OAd-IFN (OAd-IFN + (5-FU + CDDP) + 
Radiation) improving therapy efficacy (Figure 7). In summary, our data consistently 
showed that including OAd-IFN in combination with the therapeutics used in IFN-therapy 
is highly effective, especially when the virus is used in treatments that mimic the IFN-
therapy (OAd-IFN + 5-FU + radiation) Figure 4, or (OAd-IFN + (5-FU + CDDP) + 
Radiation) Figures 5 and 6. 
Despite the effectiveness of triple-combination therapies (OAd-IFN + (5-FU + CDDP) + 
Radiation) in vitro, it is possible that the inhibition of OAd-IFN by (5-FU + CDDP) 
impacted triple-combination therapy effect in vivo (Figure 6 A and B). It is clear that the 
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antagonism between OAd-IFN and (5-FU + CDDP) predicted in our in vitro experiment 
(Figure 5) translated to a diminished therapeutic effect of the virus in combination with 
chemotherapies in vivo (Figure 6). Our in vivo experiment showed that, although it is 
highly effective, the therapeutic effect of triple combinations varied when tested in two 
different experiments (Figure 6 A and B). Since tumors have irregular vascularization, 
which can affect the dose of chemotherapy delivered to tumors (238-240), the variability 
of the therapeutic effect in triple combinations in these two experiments could possibly be 
explained by the uneven delivery of chemotherapy to tumors treated with OAd-IFN + (5-
FU + CDDP) + radiation. In the triple-therapy group (Figure 6A), given that the 
chemotherapy was inhibitory to OAd-IFN, tumors that responded poorly to triple 
combinations by the end of the experiment could have received more chemotherapy doses 
than tumors that showed higher growth inhibition (Figure 6A). But although some tumors 
grew exponentially at the end of therapy in the first in vivo experiment (Figure 6A), other 
tumors in the same group showed complete remission. On the other hand, repetition of the 
in vivo experiment testing OAd-IFN combinations with (5-FU + CDDP), radiation, and (5-
FU + CDDP) with radiation (Figure 6B) did not show variability in therapeutic effect in 
the triple combination therapy. It is possible that in the second experiment all the tumors 
received similar concentrations of chemotherapy. While we did not observe any tumor 
remissions in the second in vivo experiment, tumors were consistently smaller compared 
to groups treated with OAd-IFN combined with chemotherapy or with radiation.  
Variability of therapeutic effect in the triple combination therapy in these two in vivo 
experiments could also indicate that the repeated injection of the virus during therapy is a 
variable that needs to be explored.  
It is clear that adding radiation to antagonistic combinations of the virus and 5-FU + CDDP 
surmounts chemotherapy’s inhibition of the virus in vitro and in vivo (Figures 5 and 6). 
Therefore, we propose that new radiation schedules be created in combination with OAd-
IFN (Figure 8). We showed that using radiation before infecting the tumor with the virus 
(4GY + OAd-IFN) or ((2Gy + 2Gy) + OAd-IFN) resulted in superior tumor growth 
inhibition compared to the radiation schedule that we used in our first in vivo experiments 
(Figure 8, OAd + 4Gy (1)). Although we did not test the new radiation protocol in 
combination of OAd-IFN with 5-FU + CDDP, we expect that enhancing the effectiveness 
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of the virus in combination with radiation will result in an improved triple combination 
anti-tumor effect regardless of the amount of chemotherapy regimen used. We predict that 
using radiation before viral infection will eliminate the variability of the therapeutic effect 
in triple combination, and has the potential to make this therapeutic regimen even more 
effective.  
We do not recommend, however, reducing the amount of chemotherapies used in triple 
combination because in patients PDAC is a highly heterogeneous tumor (241, 242). Using 
5-FU (a DNA-damaging base analog that further inhibits DNA and RNA synthesis) in 
conjunction with CDDP (an DNA-damaging agent) will increase the likelihood that more 
cells are affected by the treatment, whether or not they are resistant to any of the 
therapeutics used in IFN therapy (radiation, chemotherapy, and IFN). The goal of 
combination therapy is to cause cell distress and cell death through different pathways so 
that as many cancer cells as possible can be eliminated during treatment. Combining two 
DNA-damaging chemotherapy drugs with radiation (which potentiates double-strand 
break) and IFN (which enhances the effectiveness of chemoradiation) as in the IFN therapy 
protocol increases the chances that most tumor cells will be affected.  
Although chemotherapy is used consistently with OAds and has been shown to improve 
the anti-tumor effect during treatment (243-245), our preliminary studies suggested that 5-
FU inhibits OAd-IFN replication (200). The data showed that administering 5-FU before 
or after OAd-IFN infection reduces the viral DNA copy number compared to OAd-IFN 
treatment alone. Although we observed that effect, in vitro data testing combination of 
OAd-IFN with 5-FU clearly shows therapy is highly synergistic and cytotoxic (Figure 3D). 
We also show that IFN expressed by OAd-IFN enhances 5-FU cytotoxicity in PDAC cells 
(Figure 3C). On the other hand, using 5-FU + CDDP as the chemotherapy regimen 
combined with OAd-IFN eliminates the chemosensitization produced by IFN to 5-FU, and 
therapy becomes antagonistic and weakly cytotoxic. To better understand the effect of 5-
FU + CDDP in OAd-IFN, further studies accessing impact of these chemotherapies in viral 
replication need to be performed.   
 109 
The reason why addition of radiation to OAd-IFN combination with 5-FU + CDDP 
abolishes antagonism is unclear. Treatment of cancer cells with radiation and 
chemotherapies induces cellular stress, which, in turn, upregulates expression of NF-kB 
expression in treated cells (246-249). One of the activators of Cox-2—which is included 
upstream of the OAd-IFN’s E1 region and controls its replication—is NF-kB (250). It is 
possible that higher expression of NF--kB in cells treated with OAd-IFN + (5-FU + CDDP) 
+ radiation compared to the cells treated with OAd-IFN + (5-FU + CDDP) enhanced viral 
replication which contributed to triple therapy higher efficacy (Figures 5 and 6). Although 
a possible explanation, up-regulation of the NF--kB pathway must be assessed in tumor 
cells after radiation and chemotherapy treatments, and these levels should be correlated 
with virus replication. 
When cells are infected with a virus, they produce IFN which acts in an autocrine and 
paracrine manner to induce an anti-viral state in cells and shut down virus replication. We 
showed that IFN expression by OAd-IFN does not eliminate viral replication in tumors 
(Figure 7). This phenomenon can be explained by the adenovirus’ expression of VA-RNA, 
which inhibits RNA-activated protein kinase (PKR)—one of the main components of the 
IFN pathway that induces an anti-viral state in infected cell, and shuts down protein 
translation (60). IFN not only protects the cells during infection, but also acts as an 
immunomodulatory cytokine that can induce the activation and maturation of NK, T-helper 
cells, and dendritic cells, and increase MHC-1 expression in the cell surface. Therefore, as 
IFN was proven not to inhibit viral replication, using IFN-expressing OAd in IFN therapy 
can potentially stimulate an anti-tumor immune response by exposing tumor-specific 
peptides to the immune system during oncolysis. Because patients who develop an anti-
tumor immune response show higher survival rates and decreased rates of tumor recurrence 
(252-254), we believe that using an IFN-expressing OAd in IFN therapy can not only 
enhance therapy efficacy by potentiating the effect of chemotherapy and radiation by IFN, 
but it also can stimulate the formation of a robust anti-tumor response in patients and 
significantly contribute to their long-term survival after therapy. 
In summary, we conclude that using an IFN-expressing Cox-2 controlled OAd in 
combination with chemoradiation can significantly improve IFN therapy and overcome its 
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limitations. PDAC localized oncolysis and IFN expression by OAd-IFN combined with the 
highly synergistic interaction between the virus and chemoradiation indicates that the virus 
can reduce therapy toxicity while improving its efficacy. Because IFN therapy is one of the 
few therapeutic regimens shown to improve patients short- and long-term survival rates, 
developing an OAd-IFN based IFN-therapy could result in an effective PDAC treatment 
therapy. 
13. Summary 
Pancreatic cancer may soon be the third-leading cause of cancer-related death in the United 
States. Because the disease is usually diagnosed in its late stage, greater than 80% of 
patients cannot undergo surgery, which is the most effective treatment for the disease. Only 
6% of patients with PDAC who do not undergo surgery survive for five years or more and 
their post-diagnosis survival period is usually only three to four months. Despite these 
discouraging statistics, adjuvant therapy with IFN-a combined with 5-FU, CDDP, and 
radiation has produced a remarkable 35% increase in patients’ five-year survival rates. Not 
only has this therapy improved patients’ long-term survival rates, it also has improved their 
short-term survival rates by 20–41%. While this therapy is effective, its limitations include 
high IFN-associated systemic toxicity and low levels of IFN in tumors. These limitations 
prompt many patients to drop out of the therapy, diminish the beneficial effects of IFN 
during therapy, and compromise the full efficacy of the therapy.  
To overcome these limitations, we studied an IFN-expressing oncolytic adenovirus 
expressing human IFN (OAd-IFN) or hamster IFN (OAd-hamIFN) in therapeutic regimens 
that mimicked IFN therapy. 
We tested the combinations with OAd-IFN vector in an immunodeficient mice model 
bearing PDAC xenografts, and the combinations with OAd-hamIFN in a syngeneic 
immunocompetent hamster model of PDAC. Although studies in mice can display the 
interaction between therapeutic components during therapy, the hamster model 
demonstrates how the immune system can potentiate the effectiveness of conventional 
treatments.  
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Tests of IFN-expressing OAd in human or hamsters PDAC cells consistently demonstrated 
that combinations of IFN-expressing OAds with chemotherapy, radiation, and 
chemoradiation resulted in highly synergistic and effective therapies in vitro and in vivo. 
Although use of stronger chemotherapy regimen (5-FU + CDDP) with IFN-expressing 
OAd in human PDAC cells was shown to be antagonistic to virus, inclusion of radiation to 
this combination (OAd + (5-FU + CDDP) + Radiation) resulted in the most efficacious 
therapy in vitro and in immunodeficient mice bearing human PDAC xenografts. Knowing 
that radiation abolished chemotherapy antagonism to virus, we suggested to improve 
radiation protocol administered with IFN-expressing OAd. In vivo testing of new radiation 
protocols in combination with IFN-expressing OAd showed that use of radiation before 
virus infection enhanced treatment efficacy.  Thus, we recommend that this new radiation 
protocol be further explored in treatments mimicking IFN therapy.  
Our studies using the immunocompetent hamster PDAC model suggested that stimulating 
an anti-tumor immune response during treatment contribute to improved therapy efficacy. 
The data also demonstrated that the IFN expressed by the vector potentiated the effects of 
radiation and chemoradiation in vivo. These observations suggest that including an IFN-
expressing OAd in therapies that resemble IFN therapy could not only potentiate the 
therapy’s efficacy by stimulating an anti-tumor response, but it could also increase efficacy 
by potentiating IFN chemoradiosensitizaton in tumors. In addition to contributing to 
patients’ long-term survival (252-254), the stimulation of an anti-tumor immune response 
can also strengthen tumor debulking in neo-adjuvant therapies in conjunction with 
chemoradiation’s elimination of cancer cells.  Because IFN is an immunostimulant, it is 
possible that using OAd—whose oncolysis exposes tumor antigens to the host’s immune 
system— combined with chemoradiation can reduce tumor burden and make more patients 
eligible for surgery. If this effect is fully realized, OAd-based IFN-therapy could be a 
breakthrough in PDAC treatment since more than 80% of patients are excluded from 
adjuvant therapy protocols because the local PDAC is highly advanced at the time of 
diagnosis. 
In summary, our studies in hamsters and mice support including an IFN-expressing OAd 
in therapeutic protocols that mimic clinical IFN-based chemoradiation regimens. The data 
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we compiled in these two distinct models complement each other and show that 
mechanistically all the therapeutic components work well together to synergistically 
eliminate PDAC cells. The data also indicate that using IFN-expressing OAds can 
potentially stimulate tumor-specific immunity that enhances therapeutic efficacy. The 
strong synergism between IFN-expressing OAd and chemoradiation emphasizes that 
adding virus to IFN therapy could reduce associated toxicities by allowing the physician to 
reduce drug doses used in combination. Furthermore, including a Cox-2 promoter to 
control virus replication might mitigate IFN systemic toxicity by restricting and 
concentrating the production of this cytokine in PDAC tumors. These findings show that 
adding IFN-expressing OAd to IFN therapy can overcome IFN therapy’s two main 
limitations: high IFN-associated systemic toxicity and low intratumoral levels of IFN. 
Thus, we support and recommend further studies in immunocompetent hamsters to prove 
if using a replication-controlled IFN-expressing OAd in combination with 5-FU, CDDP, 
and radiation will result in a potent therapy that mimics the IFN-based chemoradiation 
regimen that was successful in PDAC clinical trials. Because this treatment protocol is one 
of the few—if not the only— protocols shown to remarkably improve the short- and long-
term survival rates of PDAC patients, developing an OAd-IFN-based IFN therapy might 
finally result in a highly effective therapy to treat this devastating disease.  
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